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Abstract 
The importance of natural regulatory T cells (nTregs) characterized by 
CD4+CD25+Foxp3+ phenotype lies in their ability to suppress pathological and 
physiological immune response, and control the responsiveness to self-antigens. Thus, 
nTregs have a pivotal role in the maintenance of self-tolerance and immune 
homeostasis. They are developed in the thymus and migrate to peripheral lymphoid 
organs to exert their suppressive function. Their development and activation is 
dependent on the interaction with antigen-presenting cells (APCs), mainly dendritic 
cells. B cells can also play a role of APC because of their high constitutive expression 
of MHC II and the ability to uptake, process and present antigens to CD4+ T cells. 
The aim of the studies presented in this dissertation was to examine the potential of 
mouse B cells as APC in the generation of thymus-derived nTregs in an in vitro 
model of co-culture of thymocytes containing nTreg precursors with splenic B cells. 
Mirroring the role of dendritic cell maturation stage  in the differentiation of induced 
CD4+CD25+Foxp3+ regulatory T cells in lymphoid organs and nTregs in the thymus, 
we decided to investigate the impact of MHC II and co-stimulatory molecules (CD80, 
CD86, CD40) expression on B cells upon activation. Imiquimod (IMQ) and 
lipopolysaccharide (LPS) were used to activate B cells through TLR7 and TLR4, 
respectively. In addition to (thymic DC and epithelial cell) a small population of B 
cells can be found in the thymus. Here the role of thymic B cells in the development 
of nTregs is discussed based on the results of preliminary studies. It is generally 
accepted that glucocorticoids acting, mainly as immunosuppressive agents, influence 
dendritic cells maturation by inhibiting the expression of MHC II and co-stimulatory 
molecules and maintaining the tolerogenic state of antigen-presenting cells. The 
impact of a synthetic glucocorticoid, dexamethasone (Dex) to induce tolerogenic B 
cells and to influence the potential of B cells to induce nTreg generation was 
investigated. 
The results of the studies presented in this dissertation are divided into three sections; 
the first section is related to the role of splenic B cells in thymus-derived regulatory T 
cells development, the second section is focused on the role of thymic B cells in the 
development of nTregs, and the third section describes the effect of dexamethasone 
on the generation of nTregs in the co-culture of thymocytes and splenic B cells. The 
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results of the study presented in the first section demonstrated that LPS- and IMQ-
activated splenic B cells upregulate the expression of MHC II and co-stimulatory 
molecules that are essential for the presentation of antigens. Both TLR4 and TLR7 
activation increased the percentage of B cells positive for particular molecules or their 
expression facilitating B cells to interact with CD4+ T cells.   
Co-culture of thymocytes with splenic B cells changed the pattern of the distribution 
of the main thymocyte subsets mainly DN CD4–CD8– and DP CD4+CD8+ with 
minor differences in the percentage of SP CD4+CD8– and CD8+CD4– independently 
on thymocytes : B cells ratio and B cell activation. However, in the microenvironment 
influenced by the presence of B cells the percentage of SP CD4+Foxp3+ thymocytes 
was increased. This phenomenon was dependent on the activation of B cells and 
thymocytes : B cells ratio. Thus, splenic B cells demonstrated the potential to generate 
nTregs in vitro dependently on the strength of co-stimulatory signals provided to 
developing thymocytes.  
In addition, the presence of splenic B cells resulted in the increase of Foxp3 
transcription factor expression. The biological activity of nTregs generated in this 
study was investigated. It was demonstrated that nTregs isolated from cultures 
maintained under different conditions statistically decreased the percentage of 
proliferating, activated, responder CD4+ T cells. Blockade of co-stimulatory 
molecules and MHC II on B cells revealed that the implication of CD80/CD86 and 
MHC II molecules was more efficient than CD40 molecule in the process of nTreg 
generation by B cells indicating to the importance of engagement of CD80/CD86 with 
CD28 molecule, while the engagement of CD40/CD40L is less important in this 
process. 
The role of thymic B cells in the generation of nTregs in vitro was presented in the 
second section. The results of 72 hours of culture revealed that activated thymic B 
cells maintained the level of nTreg generation independently of the activator used 
(LPS or IMQ), or counteracted the decrease of these cells observed in non-activated 
culture. The results revealed that thymic B cells differ from splenic B cells by their 
characteristics upon activation; in addition, activation by high concentration of LPS 
(LPS high), or low concentration of imiquimod (IMQ low) induced the increase of 
thymic B cells about 2-3-fold after 72 hours of culture compared to 24 hours of 
culture. This observation allows us to conclude that thymic B cells and splenic B cells 
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influence the generation of nTreg in different ways. In addition, the activated cultures 
showed increased expression of Foxp3 transcription factor. 
The aim of the studies presented in the third section was to investigate the potential of 
Dex to render B cells tolerogenic and in consequence to facilitate the generation of 
nTregs. The results presented in this section showed that Dex induced the decrease of 
percentage of positive B cells for co-stimulatory molecules as well as for MHC II. 
Dex did not change the distribution of thymocyte subsets nor did it influence the 
generation of thymus-derived nTreg cells.   
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1. Introduction 
The function of the immune system is to protect an individual from invader 
pathogens such as bacteria, viruses, fungi, parasites or other potential threats, while 
maintaining unresponsiveness against self-antigens or non-infectious agents (Parkin 
and Cohen, 2001; McHugh and Shevach, 2002; Powrie et al., 2003). However, our 
environment contains many other harmless organisms which can activate the immune 
system in a positive protective manner. In addition, the immune system must be able 
to discriminate between ―self‖ and ―non-self‖ to avoid attacking self-systems that 
might lead to autoreactivity resulting in autoimmune diseases. Therefore, a balance 
between tolerance to harmless and self-antigens and immunity against pathogens must 
be maintained (Banchereau et al., 2000; Shklovskaya and Fazekas de St Groth, 2007; 
Cools et al., 2007; Novak and Bieber, 2008). 
In vertebrates, the immune system is composed of innate (nonspecific) and adaptive 
(specific) immunity, arising from bone marrow-resident haematopoietic stem cells 
(HSC) (Ghia et al., 1998; Monson, 2008). The innate immunity is composed of 
mucous membranes, phagocytes and cytotoxic cells which provide non-specific first 
line defense mechanisms against pathogens. Its function is based on the recognition 
and binding of pathogens associated molecular patterns (PAMPs) through germline 
encoded patterns recognition receptors (PRRs), of which the best known are toll-like 
receptors (TLRs), expressed mainly by different types of antigen-presenting cells 
(APCs) such as macrophages and dendritic cells (Iwasaki and Medzhitov, 2004). 
PAMPs are specific conserved structures, such as lipopolysaccharide (LPS) from 
Gram-negative bacteria, which are components of bacterial cell wall. Signaling 
through TLR induces cascade of signals, which ultimately leads to rapid clearance of 
the infection (Akira and Hemmi, 2003). Pathogens that overcome this initial immune 
response are confronted by more specific line of defense, namely adaptive immunity 
(Paul, 2003). 
Adaptive immunity is composed of CD8+ T cells, CD4+ T cells, NKT cells, and B 
cells expressing clonally rearranged receptors activated after antigen encounter 
(Abbas et al., 2005). After pathogen clearance, most of the antigen-specific T and B 
cells undergo apoptosis while a few of them enter a memory pool; this ensures a 
quicker and stronger reaction during secondary infection, a process called memory 
(Yoshida et al., 2010; Li et al., 2011). 
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Rearrangement of T and B cell receptors is completely random and rearrangement 
products can be potentially self-reactive, therefore it is a vital requirement for the 
immune system to eliminate or control auto-reactive T and B cell clones in a process 
called tolerance. There are two different stages of tolerance : central tolerance that 
defines mechanisms of clonal deletion or receptor editing of developing T or B cell 
(Kappler et al., 1987; Kisielow et al., 1988; Nemazee and Burki, 1989; Boehmer, 
2009), and peripheral tolerance that refers to the control of survival and activity of 
auto-reactive lymphocyte that escaped central tolerance (Ashour and Niederkorn, 
2006). 
1.1. Innate and adaptive immunity 
Innate immunity is triggered upon pathogen recognition by PRRs. The most 
explored group of PRRs is the family of TLRs recognizing conserved molecular 
patterns shared by groups of microorganisms or viral and bacterial RNA and DNA. In 
humans, there are 11 known TLRs recognizing different PAMPs. For instance, TLR4 
binds to bacterial lipopolysaccharide found in Gram-negative bacteria cell wall, while 
TLR7 and TLR8 bind to single-stranded RNA in viruses (Medzhitov and Janeway, 
2000). So far 13 mammalian TLRs have been identified (McGettrick and O‘Neill, 
2007). Both humans and mice express TLR1–9, TLR10 is specific for humans only, 
whereas TLR11–13 are specific for mice (Chaturvedi and Pierce, 2009). 
Corresponding to the class of recognized ligands, TLRs are expressed in two distinct 
cellular compartments. In humans, TLR1, TLR2, TLR4, TLR5 and TLR6 are located 
on the outer cell membrane and recognize mainly bacterial surface-associated PAMPs 
such as peptidoglycan and lipopeptides (TLR1, 2, 6), lipopolysaccharide (TLR4), and 
flagellin (TLR5). The other human TLR are expressed on the membrane of 
intracellular endosomes and bind to viral dsRNA (TLR3), ssRNA (TLR7 and 8), and 
unmethylated bacterial DNA (TLR9) (Chaturvedi and Pierce, 2009; Takeda and 
Akira, 2005). 
One of the major contributions of the innate immunity is the barrier function of the 
epithelial surfaces preventing entry of microbes into the body. Other mechanisms 
include mucin production by certain epithelia, and release of anti-microbial factors 
such as defensins, lysozyme, and lactoferrin (Ouellette, 1989;1994; Mestas and 
Hughes, 2004). Mucins act as a highly viscous, protective layer entrapping 
microorganisms on the apical surface of epithelial cells. Antimicrobial peptides can be 
produced constitutively or induced by microbial molecules binding to TLRs. 
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Any infectious agent crossing the epithelial barrier should be recognized by TLRs on 
resident macrophages and induce a cascade reaction leading to elimination of the 
invading pathogen through various mechanisms including phagocytosis and 
intracellular killing of the microorganism by macrophages and neutrophils, or direct 
killing by defensins or lysozyme. Another important innate immunity mechanism is 
activation of the complement system via alternative or lectin pathways. This leads to 
the deposition of C3b on the surface of the microorganism, which acts as an 
opsonizing agent promoting microbial uptake by phagocytic cells. As a consequence 
of complement activation membrane-attack complex is formed that results in lysis of 
the pathogen. Phagocytic cells release different cytokines, which in turn can induce 
the mobilization of antigen-presenting cells (APCs) that are important for the 
induction of the adaptive immunity (Male et al., 2000). 
Lymphocytes are the central players of adaptive immunity. There are two main 
populations of lymphocytes: T lymphocytes (T cells) responsible for cell-mediated 
immunity and immune regulation (McHugh and Shevach, 2002; Powrie et al., 2003; 
Fujio et al., 2010; Luckheeram et al., 2012), and B lymphocytes (B cells), responsible 
for humoral immunity (Youinou , 2007; Vitale et al., 2010) . In contrast to innate 
immunity, adaptive immunity is highly specific and is able to recognize small 
structural fragments (called epitopes) on foreign molecules (antigens). It is also highly 
effective in complete elimination of the invading micro-organism. Circulating 
antibodies are the effector molecules of humoral immunity. They bind to epitopes of 
foreign antigens and contribute to the elimination of pathogens in various immune 
reactions. In cell-mediated immunity the effectors are cytotoxic CD8+ T cells and a 
variety of cytokine producing T cell populations.  
B and T cells utilize highly specific receptors. B cells use cell-membrane bound 
immunoglobulin (mIg) molecules (BCRs, B Cell Receptors). Upon activation B cells 
proliferate, differentiate into plasma cells, and secrete immunoglobulins (soluble 
antibodies) providing defense against pathogens in the extra-cellular spaces of the 
body. The largest population of T cells, Tαβ cells, have specific receptors (TCRs, T 
Cell Receptors) that recognize small peptides derived from protein antigens presented 
on the surface of antigen-presenting cells (APCs) in context of major 
histocompatibility complex molecules (MHC). MHC I-peptide complexes are 
recognized by TCRs of CD8+ T cells, while CD4+ T cell TCRs bind to MHC II-
peptides. Depending on the type of  activated T cells, the activation might result in 
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killing of infected target cells by cytotoxic CD8+ T cells, activation of macrophages 
and B cells by different effector helper CD4+ T cells or inhibition of the activity of 
various adaptive and innate immune cells by regulatory T cells induced upon 
activation. 
The adaptive immunity is highly specific and each encounter of a new foreign antigen 
will induce long-lived specific memory cells that will protect an individual from re-
infection with the same pathogen. Memory cell repertoires are changing during the 
life span of individual resulting in increased protection throughout the life and tend to 
decrease when the immune system starts to senesce. Innate immune responses 
recognize generic targets on pathogens using germ line encoded receptors, whereas 
adaptive immune response recognizes specific targets using randomly generated 
receptors which have a virtually unlimited recognition repertoires. 
1.2. Regulatory T cells: phenotype, origin and suppressive mechanisms 
It is very well documented that regulatory T cells (Tregs) are involved in the 
maintenance of tolerance and immune homeostasis. In one of the recent papers, 
Sakaguchi classifies the mechanisms of tolerance and immune homeostasis as 
recessive and dominant (Sakaguchi et al., 2008). In the recessive mechanisms, the fate 
of autoreactive lymphocyte exposed to self-antigen is determined by intrinsic manner. 
Most immature thymocytes are programmed to die by apoptosis when exposed to self-
antigens associated with MHC. The activation threshold of thymocytes and T cells in 
peripheral lymphoid organs may be increased by the induction of negatively 
regulating proteins (inhibitory receptors, negative signaling molecules). On the other 
hand, the cells may not survive because of activation induced cell death. This cell- 
intrinsic control of the cell fate also contributes to the inhibition of an excessive 
response to non-self/conventional antigens. In dominant (extrinsic) mechanism 
requires T cells with specialized suppressive activity, namely T regulatory cells. In 
addition, it is considered that every immune response generates both effector and 
suppressive cells. 
1.2.1. Phenotype and origin 
There are two populations of Tregs distinguished on the basis of generation 
site (Fig. 1.1): thymus-derived Tregs (tTregs) also named natural Tregs (nTregs) 
developed in the thymus and peripherally-derived Tregs (pTregs) known also as 
induced Tregs (iTregs) that differentiate from conventional naïve CD4+Foxp3− T 
cells after antigen exposure under particular conditions in peripheral lymphoid organs 
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(Sakaguchi et al., 1995; King and Sarvetnick, 1997; Groux et al., 1997; Weiner, 2001; 
Elkord, 2014). Natural regulatory T cells are developed in the thymus as  functionally 
mature suppressive T cell population, whereas iTregs are generated in the periphery 
after cognate antigen challenge (Wing and Sakaguchi, 2010). Many cell surface 
markers were described as expressed by nTregs but there is no specific molecule 
considered as specific marker to distinguish them from iTregs in peripheral lymphoid 
organs.  
 
 
Figure 1.1:—Populations of Tregs and effector T helper cells depending on the site of generation. 
Tregs are either generated naturally by thymic differentiation (nTreg) or are induced in the periphery 
(iTreg) from naïve T helper cells (TH0, naive helper T cells). Subpopulations of iTreg include TH3 
inhibiting the immune response mainly through TGF-β and interacting with B cells to enhance or 
inhibit their activity, Tr1 suppressing autoimmune response and tissue inflammation partly through 
secretion of IL-10. The main effectors differentiating from T helper cells include TH1, TH2, and TH17. 
(Peterson, 2012). 
 
It has been suggested that regulatory T cells are defined by the expression of the 
forkhead family-transcription factor X-linked forkhead/winged helix (Foxp3). 
Foxp3 expression is required for regulatory T cell development and function 
(Fontenot et al., 2003; Khatteri et al., 2003; Hori et al., 2003), and this transcription 
factor control a genetic program specifying this cell fate (Marson et al., 2007). Foxp3 
Thymus-Derived 
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was initially identified as the gene responsible for an X-linked recessive inflammatory 
disease in scurfy mutant mice, and further in humans for the fatal 
autoimmune/inflammatory disease, immune dysregulation, polyendocrinopathy, 
enteropathy, X-linked syndrome (IPEX) (Brunkow et al., 2001; Wildin et al., 2001), a 
severe autoimmune disease that develops early in infancy. In mice, Foxp3 is almost 
exclusively expressed intracellularly in nTregs and iTregs. In humans, its expression 
is also detected in peripherally generated regulatory T cells (Fehervari and Sakaguchi, 
2004). Although Foxp3 appears to be required for human Treg development and 
function, expression of Foxp3 alone is not sufficient as a significant percentage of 
human activated T cells express Foxp3 and yet do not exert suppressive activity 
(Wang et al., 2007). Furthermore, induction of Foxp3 in human T cells by 
transforming growth factor-β (TGF-β) does not confer regulatory phenotype, in 
contrast to their murine counterparts (Tran et al., 2007). The absence of functional 
Foxp3 results in severe systemic autoimmune diseases in mouse and human. It has 
been shown that Foxp3 inhibits IL-2 transcription and induces up-regulation of Treg-
associated molecules, such as CD25, GITR (glucocorticoid-induced TNFR-related 
protein) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) (Shevach and 
Stephens, 2006), that can down-regulate the immune response of adjacent cells, 
(Table 1). 
Table 1: Molecules expressed by Tregs (nTregs and iTregs) constitutively or upon activation. 
Molecule nTreg iTreg Functions Refer nces 
Foxp3 + +/ ─ Master regulator (development 
and function) 
Zhang and 
Zhao, 2007 
CD4 + + Co-receptor for APCs (interact 
with MHC II) 
Brady et al., 
1993 
CD25 + + High-affinity receptor for IL-2 
(IL-2Rα) 
Janeway et al., 
2001 
CD28 + + Co-receptor molecule (interacts 
with CD80 and CD86), transmits 
an activatory signal to T cell 
Harding et al., 
1992 
CD152 
(CTLA-4) 
+ + Co-receptor molecule (interacts 
with CD80 and CD86), transmits 
an inhibitory signal to T cell 
Walunas et al., 
1994 
 - 26 - 
CD278 
(ICOS) 
? +/? Co-stimulatory molecule 
involved in cell-cell signaling, 
immune response, and regulation 
of cell proliferation 
Guedan et al., 
2014 
GITR + + Inhibits suppressive activity of 
regulatory T-cells and increases 
survival of effector T-cells 
Shimizu et al., 
2002 
CD69 + + Signal-transmitting receptor in 
lymphocytes involved in 
lymphocyte proliferation and 
functions  
Tough et al., 
1997 
CD103 
(HML-1, 
integrin α E) 
+ +/? Important for T cell homing to 
the intestinal sites 
Agace et al., 
2000; Huehn  et 
al.,2004; 
Shimizu et al., 
2003 
CD38 + + Multifunctional ectoenzyme that 
catalyzes the synthesis and 
hydrolysis of cyclic ADP-ribose 
(cADPR) from NAD
+
 to ADP-
ribose 
Read et al., 
1998 
Fas (CD95) + + Transduces apoptotic signal from 
T cells to target cells 
Suda and  
Nagata, 1997 
CD154 
(CD40L) 
+ + Co-stimulatory molecule Danese et al., 
2004 
CD223 
(LAG-3) 
+ ? May have a negative regulatory 
function. 
Workman et al., 
2004 
CD31 
(PECAM-1) 
+ ─ A member of 
immunoglobulin superfamily 
involved in leukocyte 
transmigration, angiogenesis, and 
 integrin activation 
Marson et al., 
2007 
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CD62L  
(L-selectin, 
LECAM1) 
+ +/? Adhesion molecule involved in 
cell activation and circulation, 
also acts as a "homing receptor" 
for lymphocytes to enter 
secondary lymphoid tissues via 
high endothelial venules 
Robbins et al., 
1998;    
Gomes-Pereira 
et al., 2004  
CD127 (IL-
7R α-chain) 
+ +/? Involved in T cell proliferation Seddon and 
Zamoyska, 
2002 
CD39 and 
CD73 
+ +/? CD39 and CD73 ectonucleotidase 
activity generates pericellular 
adenosine, which inhibits various 
activated immune cell types in an 
A2AR-dependent cAMP- fashion 
Bynoe and Viret, 
2008; Antonioli 
et al., 2013 
CD45RA, 
CD45RO 
? +/? Signaling molecules that regulate 
a variety of cellular processes 
including cell growth, 
differentiation, mitotic cycle, and 
oncogenic transformation  
Seddiki et al., 
2006; Fukuhara 
et al., 2002 
CD49d 
(VLA4α, 
Integrin α4) 
─ +/ ─ Key mediator of T cell entry into 
the CNS 
Vajkoczy et al., 
2001; 
Kleinewietfeld  
et al., 2009 
CD101 
(IGSF2, V7) 
? +/? Correlated with functional 
suppressor activity of CD4+ 
CD25+ Treg cells in mice 
Fernandez et 
al., 2007 
FR4 + ? Plays an important role in the 
maintenance of Treg phenotype 
Tian  et al., 
2012 
CD26 
(Dipeptidyl 
peptidase-
4 (DPP4) 
? +/?  Plays a major role in glucose 
 metabolism. It is responsible for 
the degradation of incretins such 
as GLP-1 
Barnett, 2006 
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Accumulating evidence suggests that nTregs express some molecules constitutively 
and other molecules upon activation. They appear to constitutively express a variety 
of molecules, such as CD25 (interleukin-2 receptor α-chain, IL-2Rα) at a high level, 
CD62L, CD28, CD127, CD103, CD152 (cytotoxic T-lymphocyte-associated antigen 
4, CTLA-4), and GITR (glucocorticoid-induced tumor necrosis factor receptor, also 
known as TNFRSF18) (Harding et al., 1992; Walunas et al., 1994; Robbins et al., 
1998; Agace et al., 2000; Janeway et al., 2001; Shimizu et al., 2002; Seddon and 
Zamoyska, 2002). Other cell surface receptor molecules include galectin-1, CD38, 
CD252 (OX-40L), TNFR2, and TGF-βR1. nTregs also express high levels of CD5, L-
selectin, and CD45RO, while expressing low levels of CD45RC (Piccirillo and 
Thornton, 2004; Mills, 2004).There is a great interest in identifying cell surface 
markers that are uniquely and specifically expressed on all Foxp3-expressing 
regulatory T cells.  
Some properties of nTregs have been well documented, whereas others need more 
investigations. It has been shown in vitro that nTregs are anergic in the presence of 
conventional T cell stimuli such as plate-bound anti-CD3. Anergy can be prevented 
by additional important stimuli, for instance, IL-2 and IL-15, which can also abolish 
suppressive properties of nTreg cells (Koenen et al., 2003; Fehervari and Sakaguchi, 
2004). 
 nTregs represent about 5–10% of the peripheral CD4+ T cell population (Jonuleit et 
al., 2001; Shevach, 2001; Sakaguchi, 2004). However, in human blood this population 
consists of hardly distinguishable mixture of nTregs and iTregs, and thus some 
authors estimate the content of nTregs at 1–2% (Ng et al., 2001). Furthermore, in vitro 
studies have shown that CD4+CD25
high
 T cells appear to be a homogeneous 
population of suppressor cells that do not contain memory or activated T cells. The 
suppressive effect is mediated by a direct cell-cell interaction–dependent, cytokine-
independent mechanism that requires activation of these cells via a T-cell receptor 
(Nakamura et al., 2001; Jonuleit et al., 2002; Thornton et al., 2010). 
Although nTregs are perhaps more abundant in a steady state of immune system, 
iTregs may play an important role in maintaining proper immune function and 
regulation (Bluestone and Tang, 2005). While nTregs need co-stimulation via CD28, 
iTregs do not need any co-stimulation (Kretschmer et al., 2005). 
Many investigators have shed a light on nTregs for their important role in maintaining 
homeostasis of immune system, tolerance to self-antigens, and suppressing excessive 
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response to pathogens. nTregs can suppress a wide spectrum of innate as well as 
adaptive immune cells, including CD4+ T cells, CD8+ T cells, B cells, monocytes, 
NK and NKT cells, and DCs (Cosmi et al., 2003; Fehervari  and Sakaguchi, 2004; 
Grossman et al., 2004; Piccirillo, 2004; Mills, 2004; Bruder et al., 2004; Huang  et al., 
2004; Sakaguchi et al., 2008). nTregs actively suppress the proliferation and cytokine 
production of conventional CD4+ T and CD8+ T lymphocytes. They act at an early 
stage of autoimmune gastritis progression to inhibit the differentiation of naive T 
CD4+ cells to pathogenic T helper 1 (Th1) effectors (Shevach et al., 2006), or into T 
helper 2 (Th2) (Xu et al., 2003) and suppress their immune response preventing from 
autoimmunity (Stummvoll et al., 2008). Recent evidence indicates that the use of 
Tregs (CD4+Foxp3+) is one of the promising approaches to control Graft-versus-Host 
Disease (GvHD) in different mouse models (Cohen et al., 2002; Hoffmann et al., 
2002; Edinger et al., 2003; Trenado et al., 2003; Taylor et al., 2004; Ermann et al., 
2005).  
Tregs have shown a promising potential in therapy of autoimmune diseases and organ 
transplantation (Albert et al., 2006). Recently, it was found that Tregs exert an 
inhibitory effect on Th17 differentiation and IL-17 production, similarly to the effect 
on Th1 and Th2 differentiation (Chaudhry et al., 2009). However, some reports 
indicate that Th17 cells are not inhibited but rather enhanced by Tregs (Lohr et al., 
2006; Veldhoen et al., 2006). Investigations of the role of Tregs on IL-17 production 
in the absence of exogenous polarizing cytokines showed that simultaneous activation 
of naïve conventional T cells and Tregs in the presence of antigen-presenting cells 
induced differentiation of Tregs into IL-17 producers (Li et al., 2010), but not 
conventional T cells. 
1.2.2. Mechanisms of suppression  
Significant progress has been made, since Sakaguchi and his co-workers 
published their landmark results in 1995, in delineating the molecules and 
mechanisms used by Tregs to mediate suppression (Sakaguchi et al., 1995). It has 
been accepted that Tregs are activated by either antigen-specific TCR ligation or the 
presence of polyclonal stimuli (Takahashi et al., 1998; Thornton and Shevach, 1998). 
However, after activation Tregs are able to exert their inhibitory functions in a non-
antigen specific manner (Takahashi et al., 1998; Thornton and Shevach, 2000). Cell-
to-cell contact between the suppressor and target cells is required for nTreg-mediated 
suppression (Nakamura et al., 2001; Jonuleit et al., 2002), as was shown in 
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experiments utilizing semipermeable membrane to separate nTregs from T effector 
cells; or transfer of nTreg supernatants onto effector cells. In both cases the 
suppression of T effectors did not occur (Ng et al., 2001). However, is still not clear 
which population, Th cells or APC cells, is controlled by nTregs (Shevach et al., 
2001).  
The presence of Treg cells is associated with decreased proliferation of T effector 
cells (Sakaguchi et al., 1995; Ng et al., 2001; Baecher-Allan et al., 2001), their 
cytokine production (Oberle et al., 2007), and altered chemokine receptor expression 
(Lee et al., 2004; Sarween et al., 2004). In addition to in vitro findings, Tregs have 
been shown to inhibit the expansion of T effectors in vivo (Edinger et al., 2003). It 
was found that alloantigen expression by the host APCs is necessary and sufficient for 
protection of GvHD by donor Tregs (Tawara et al., 2010). Inhibition of IL-2 
transcription in the target cells seemed to be the main mechanism of suppression 
(Thornton and Shevach, 2000). Although the down-regulation of IL-2 is often used as 
a readout of Treg function, it is not clear if IL-2 is the primary molecular target of 
suppression (Sojka et al., 2008; Wang et al., 2010). Because of the indiscriminate 
nature of Treg suppression, the important antitumor immune response may also be 
suppressed, which may allow the progression of various types of tumors. Therefore, 
immunologists have been working to define Treg cells at the molecular level 
(Sakaguchi et al., 2007; Costantino et al., 2008; Agarwal et al., 2014).  
Tregs use different mechanisms to exert their suppressive potential against target 
cells. It is not known what determines the use of a specific mechanism of suppression.  
● Inhibitory cytokines 
It is considered that cytokines, namely IL-10, TGF-β, and IL-35 are used by 
different Tregs for suppressing target cells (Fig. 1.2). In contrast to nTregs, most 
iTregs mediate suppression predominantly via cytokine-dependent pathways 
(Berthelot and Maugars, 2004). Functionally, IL-10 and TGF-β can induce peripheral 
iTregs (Tr1 and Th3 respectively, see Fig. 1.2). In addition, TGF-β plays an important 
role in the induction of Foxp3+Tregs both in vivo and in vitro (Chen et al., 2003; Liu 
et al., 2008) and plays a role in Tregs homeostasis (Marie et al., 2005). Activation of 
naive T cells in the presence of TGF-β induced Foxp3 expression and differentiation 
of iTreg cells (Chen et al., 2003; Zheng et al., 2004; Kretschmer et al., 2005). TGF-β1 
was shown to induce IL-10 production in Th1 cells (Cottrez and Groux, 2001), which 
further inhibited cytokine production and directly attenuated T effector cell function 
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(Annacker et al., 2001). IL-10 enhanced the response of activated T cells to TGF-β1 
through regulation of TGF receptor expression (Cottrez and Groux, 2001).  
Some types of iTregs exert suppressive function by producing inhibitory-cytokines 
such as IL-10. In this mechanism Tregs can suppress differentiation of Th1 and Th2 
cells directly by reducing IL-2, TNF-α, and IL-5 production, and indirectly by down-
regulation of MHC and co-stimulatory molecules on APC, thereby reducing T cell 
activation. The mechanism of suppression will most likely depend on the type of 
Treg, the strength of stimuli, the nature of the immune response, and the site of 
inflammation (Vignali et al., 2008). However, the effects of IL-10 as 
immunosuppressive cytokine have been well documented in different diseases 
(McGeachy and Anderton, 2005; Belkaid, 2007; Rubtsov et al., 2008). IL-10 plays an 
important role in Treg-mediated suppression of intestinal inflammation, since 
blocking IL-10 or using IL-10 deficient Tregs abrogates the protective effect of Tregs 
on T cell transfer-induced colitis (Asseman et al., 1999). 
TGF-β is a regulatory cytokine with pleiotropic functions in control of T cell 
responses (Li and Flavell, 2008). Generally, three members of TGF-β family have 
been identified, which designated as TGF-β1, TGF-β2, and TGF-β3. In early studies 
they were defined as negative regulators of T cells, since the addition of TGF-β to 
cultures inhibited T cell proliferation (Kehrl et al., 1986). Recent results have shown 
that co-culture of nTregs with T helper cells resulted in the differentiation of Th cells 
into Treg cells suppressing Th1 or Th2 cell responses in a TGF-β1 and/or IL-10-
dependent manner in vitro (Jonuleit et al., 2002). In addition, TGF-β can exist in two 
forms: soluble and membrane-bound (Nakamura et al., 2001). Probably the 
membrane-bound form of TGF-β mediates inhibitory signals during direct interaction 
between nTregs with target cells (von Boehmer, 2005). Tumor suppressing activity of 
TGF-β is directed toward activated macrophages, T and B lymphocytes, and NK cells. 
Similarly to IL-10, TGF-β inhibits the expression of the MHC II on antigen 
presenting cells. Mode of action of TGF-β depends on the concentration of IL-2: 
naïve CD4+ T cells cultured with high concentration of IL-2 up-regulate CD25, IL-2 
receptor beta-chain (CD122), and CTLA-4 that results in the activation and 
differentiation of these cells into iTreg cells (Zheng et al., 2004). 
IL-35 is a newly discovered inhibitory cytokine, which may contribute substantially to 
the function of Treg cells directly acting on responder T cells and inhibiting their 
proliferation (Collison et al., 2007). IL-35 is a member of the IL-12 heterodimeric 
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cytokine family and constitutes a heterodimer between Epstein-Barr virus-induced 
gene 3 (Ebi3, which normally pairs with p28 to form IL-27) and Il12a (known as p35 
that normally pairs with p40 to form IL-12 p70). IL-35 is a potent inhibitory cytokine 
produced by Tregs that suppresses T cell proliferation by inducing cell-cycle arrest in 
G1 phase without induction of apoptosis (Cottrez and Groux, 2001; Casella et al., 
2014). However, unlike mouse Tregs, human Tregs do not show any tendency to 
constitutive expression of IL-35 (Bardel et al., 2008). Recently, it was indicated that 
treatment of murine or human naïve T cells with IL-35 induced iTregs-35 that can 
exert suppressive activity via IL-35 (Collison et al., 2010).  
● Cytotoxic effects by induction of apoptosis 
Targets for the cytotoxic effects include CD4+ T cells, CD8+ T cells, B cells, 
monocytes, and DCs. However, as mentioned above, many studies have demonstrated 
that mechanisms used by nTregs to suppress responder cells in vitro require cell-to-
cell contact (Shevach et al., 2001). Thus, nTregs can exert cytotoxic effect on target 
cells via release of perforin and granzyme (Likuni et al., 2009), or via Fas/FasL 
interaction (Hirohata, 1997) (Fig. 1.2). Fas (CD95) is a type I membrane protein in the 
tumor necrosis factor receptor family (Nagata and Golstein, 1998). FasL (CD95L) is a 
transmembrane protein, and soluble FasL trimmers can be generated by a 
metalloproteases (Tanaka et al., 1998). The cytotoxic effects of nTregs against 
effector T cells have been well documented, whereas the mechanism of nTreg 
cytotoxic effect upon B cells was less studied and needs further investigations.  
The requirement for cell-cell contact for nTreg suppressive activity have been 
investigated using transwell experiment model allowing to segregate between nTregs 
and effector T cells. It has revealed that murine Treg cells can induce cytotoxic effect 
toward responder T cells by granzyme and/or perforin-dependent mechanism 
(Gondek et al., 2005). The main function of Fas is to transduce pro-apoptotic signals 
from cells that express FasL (regulatory T cells) to cells that express Fas (target cells). 
The induction of apoptosis is therefore involved in self-tolerance by elimination of 
unwanted cells such as autoreactive-T and B cells.  
Other results from transgenic mouse models have suggested that CD4+ T cells may 
play an important role in the elimination of peripheral autoreactive B cells through 
MHC class II/T cell receptor, CD40/CD40L, and Fas/FasL interactions (Rathmell et 
al., 1995; Rathmell et al., 1996). In addition to perforin/granzyme and Fas/FasL 
manner, nTregs use other factors that are potentially involved in killing the target 
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cells. These molecules include LAG-3 (Huang, 2004), membrane-bound TGFβ 
(Nakamura et al., 2001), cytotoxic T-lymphocyte antigen 4 (CTLA-4) (Tang et al., 
2004; Read et al., 2006), galectin-1 (Garin et al., 2007), and programmed death-1 
(PD-1) (Kornete and Piccirillo, 2011). All these molecules provide negative co-
stimulation to target cells. 
● Metabolic disruption 
IL-2 is a critical cytokine in promoting survival and proliferation of T cells, by 
mediating differentiation and maturation of T cells into effector and memory T 
cells upon antigen activation of naïve T cells. Furthermore, IL-2 critically regulates 
several populations of mature peripheral Treg and antigen-activated conventional T 
cells. Additionally, in the thymus, IL-2 prevents autoimmune diseases by promoting 
the differentiation of certain immature thymocytes into natural  regulatory T cells, 
which eliminates T cells that are primed to attack healthy tissues in the body (Liao et 
al., 2011). Its expression and secretion is tightly regulated.  
In addition to the role of IL-2 in the development of T cell immunologic memory, 
which depends upon the expansion of the number of antigen-selected T cell clones, it 
also plays a key role in enduring cell-mediated immunity (Malek and Castro, 2010; 
Liao et al., 2011). Functionally, nTregs show a marked hypoproliferation upon 
TCR/CD3-mediated stimulation (Sakaguchi et al., 1995; Ng et al., 2001), which can 
be overcome by the addition of high doses of IL-2 (Thornton and Shevach, 1998).  
Several types of Tregs are described as CD25+ and it is suggested that nTregs express 
high level of this molecule. This property gives the advantage to Tregs in the 
competition with effector T cells for binding with IL-2, that is important in 
maintaining homeostasis by nTreg in vivo (Yu et al., 2009)  and crucial for their 
suppressive activity in vitro (Thornton et al., 2004). In addition, nTregs can also 
deplete IL-2 through binding to their constitutively highly expressed IL-2 receptor 
and subsequent internalization. Consequently, effector T cells, which are deprived 
from IL-2 by this mechanism, undergo apoptosis after 72 h of co-culture (Pandiyan et 
al., 2007) (Fig. 1.2). According to some authors, nTreg cells can suppress effector T 
cells through the inactivation of IL-2 transcription (Thornton and Shevach, 1998; 
Oberle et al., 2007). Other studies in the hybrid system have shown that human 
regulatory T cells can effectively inhibit the proliferation of effector T cells; however, 
the addition of human anti-CD25 antibodies blocking and binding IL-2 did not affect 
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the function of human regulatory T cells (Tran et al., 2009; Yu et al., 2009). Thus, the 
issue of participation of IL-2 as a target of suppressor cells remains controversial. 
● Suppression of dendritic cells 
Natural regulatory T cells can suppress T effector functions by modulating the 
maturation and function of dendritic cells that are required for activation of effector T 
cells (Bluestone and Tang, 2005). One of the molecules involved in this process is 
CTLA-4, an inhibitory molecule highly expressed by nTregs (Takahashi et al., 1998; 
Read et al., 2000). The results show that CTLA-4-deficient mice develop autoimmune 
diseases similar to those formed in the absence of T regulatory cells (Wing et al., 
2008). CTLA-4 may participate in the suppressive activity of nTregs in two ways 
(Fig. 1.2). CTLA-4 interaction with co-stimulatory molecules (CD80/CD86) on 
dendritic cells results in inhibition or reduction of their expression. Reduced 
expression of CD80 and CD86 molecules on APCs weakens the co-stimulatory signal 
needed for the effector T cell, thereby suppressing their activation (Onishi et al., 
2008). It has also been suggested that the engagement of CD80 and, to a lesser extent, 
CD86 on the responder T cells was responsible for the negative signal given by Treg 
cells (Paust et al., 2004). In addition, CTLA-4 interaction with the same molecules on 
DCs  triggers the induction of indoleamine 2,3-dioxygenase (IDO) by DC, which 
catalyzes the tryptophan conversion into kynurenine, molecules showing 
immunosuppressive effects on several cell types , including effector T cells (Fallarino 
et al., 2003; Mellor and Munn, 2004). 
Another molecule involves in the suppression of dendritic cells is LAG-3. It is a 
homolog of CD4 that binds with high affinity MHC II on immature dendritic cells. 
The binding of LAG-3 to MHC II induced the inhibitory intracellular signaling 
pathway through ITAM motifs, and resulted in inhibition of dendritic cell maturation 
and their ability to activate effector T lymphocyte via FcγRγ (Liang et al., 2008). 
Neuropilin-1 (NRP-1) can also modulate suppressor activity of nTregs. NRP-1 
contributes to elongation of interaction between nTreg and dendritic cell, which 
restricts access of effector T cells to effective antigen presentation (Sarris et al., 
2008). 
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Figure 1.2:— Treg-mediated suppressive mechanisms. 
1/ Inhibitory cytokines, IL-10, TGF-β, and IL-35 can suppress T cell activation. 2/ Induction of 
apoptosis of target effector T cells in a granzyme A- and B-dependent fashion. 3/  Cytokine 
deprivation, through binding of IL-2, leads to metabolic disruption of target cells or direct cAMP 
mediated inhibition. 4/ DC are targeted via direct cell-cell interactions, via CTLA-4 or via suppressive 
cytokines such as IL-10 (Broere et al., 2011). 
 
1.3. Thymus-derived regulatory T cell development in the thymus 
Jacques Miller in 1961 has indicated the thymus as the place for lymphocyte 
development (Miller, 1961; 2002). After one year of this landmark discovery, he 
described the role of thymus as a place of immunological tolerance (Miller, 1963). 
Natural regulatory T cells arise in the thymus through sequential steps of 
thymopoiesis. It is constitutively express Foxp3 transcription factor, and these cells 
are first detected at the thymocyte CD4 + single-positive (SP) stage (Hori et al., 2003). 
Studies on Foxp3 protein expression at the single cell level in humans have confirmed 
that a small proportion of Foxp3+ cells are CD8+ and that Foxp3 expression is also 
present in a minority of CD25– T cells (Roncador et al., 2005). However, a few 
Foxp3+ thymocytes are also detected at the double positive (DP) CD4+CD8+ stage 
but most of these cells are artifacts caused by the formation of doublets of  
CD4+CD8+Foxp3– and CD4+Foxp3+ cells in FACS analysis (Lee and Hsieh, 2009). 
Nevertheless, Foxp3+ cells were also found in both DP and SP CD8+ populations. 
Positive and negative selection represent two crucial checkpoints that occur during 
thymocyte development. At this point in development, randomly rearranged TCRs act 
in concert with CD4 and CD8 co-receptors to interact preferentially with either MHC 
class II or MHC class I, respectively (Kaye et al., 1989; Scott et al., 1989). This 
 - 36 - 
engagement of TCR/co-receptor with MHC-self peptide complexes in positive 
selection is vital in generating T cells that can bind to self-MHC ensuring MHC 
restriction. In addition to that, negative selection allows elimination of potentially 
autoreactive thymocytes and in consequence the state of T tolerance is assured. A 
landmark study of thymocyte selection showed that over 97% of all thymocytes that 
become DP cells die because of their inability to recognize, at any level, the presence 
of MHC and therefore will not receive survival signals through the TCR (Huesmann 
et al., 1991). These cells are said to die by neglect. The remaining thymocytes are 
thought to survive initially by the recognition of low-affinity TCR-MHC-self peptide 
complexes interactions. 
Signals that influence the development of nTregs in vivo are not clear yet. On the 
other hand, it is known that nTreg development is affected by different factors such as 
co-stimulatory molecules, cytokines, and TCR affinity. The most proximal precursor 
to nTreg cells is a CD4+CD25+Foxp3– thymocyte that under the proper conditions 
further matures into a Foxp3+ Treg cell that is able to exert suppressive function 
(Burchill et al., 2008; Lio and Hsieh, 2008). 
Thus, a two-step model for nTreg differentiation has been proposed in which 
TCR/CD28 signals first induce the differentiation of nTreg precursors with increased 
sensitivity to IL-2/IL-15, then induce the expression of Foxp3 by IL-2/IL-15 signaling 
in a STAT5-dependent TCR-independent manner (Fig. 1.3) (Burchill et al., 2008; Lio 
and Hsieh, 2008; Goldstein et al., 2013). nTregs represent a minor population of 
thymocytes, i.e. about 4% of the SP CD4+ thymocytes (Fontenot et al., 2005), and 
between 5-10% of CD4+ in the periphery (for CD4+CD25+Foxp3+ cells including 
nTregs and iTregs) (Shevach, 2002; Sakaguchi, 2004).  
There are two different mechanisms of T cell tolerance: central tolerance representing 
the clonal deletion or receptor editing of developing T cells in the thymus before they 
export to the periphery and peripheral tolerance related to the suppression of 
autoreactive T cells that escaped central tolerance and circulate in the periphery 
(Palmer, 2003; Stockinger, 1999). Both central and peripheral tolerance of T cells are 
crucial in preventing the onset of autoimmunity. nTreg cells are generally considered 
a key mediator of peripheral tolerance, as they are able to suppress self-reactive T and 
B cells and efficiently prevent autoimmunity (Piccirillo and Shevach, 2004; Fields et 
al., 2005). As nTregs originate in the thymus, it is thought they initially undergo the 
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same selective pressure and developmental checkpoints as conventional T αβ cells 
(Bettini and Vignali, 2010). 
 
      Immature                Immature nTreg           nTreg                               nTreg    
     lymphocyte                    precursor                 precursor  
 
Figure 1.3:— A hypothetical model for nTreg development in the thymus. 
A/ Immature CD4+ thymocytes are engaged by strong agonist TCR/co-stimulatory signals, which 
results in the expression of CD25. B/ Subsequent interaction of immature nTreg precursors with 
CD122 signaling cytokines IL-2 and IL-15 leads to STAT5 phosphorylation to generate nTreg 
precursors. C/ Following continuous engagement of CD122, Foxp3 expression is induced in nTreg 
precursors to generate fully functional nTregs (Goldstein et al., 2013). 
 
There are two models that describe development of nTregs in the thymus. In ―kinetic 
signaling‖ model (Bosselut et al., 2001) signal intensity allows for positive selection 
and then signal duration allows for CD4/CD8 lineage commitment. Recently, a 
variation of the kinetic signaling model has been proposed in which serial low affinity 
triggering by peptide-MHC complexes can promiscuously ligate enough TCRs to 
generate a persistent signal (Valitutti et al., 1995). In contradiction to this model, it 
has been shown that MHC class I-restricted thymocytes lacking CD8 can be driven to 
choose the CD8 lineage by interacting with high-avidity ligands (Goldrath et al., 
1997). Furthermore, CD4+CD8
lo/−
 thymocytes are not always observed within TCR 
transgenic mice as seen in some mice that express MHC class I specific TCRs 
(Hogquist, 2001). Both of these rare observations may be seen in default pathways to 
allow survival of thymocytes when selective pressures are applied. Regardless of the 
detailed events in positive selection, less than 1% of all thymocytes will recognize 
self-peptide at affinity/avidity high enough to receive survival signals but also low 
enough to avoid the activation threshold for apoptosis (Allen, 1994; Santori et al., 
2002). The recognition of self-peptide with high affinity/avidity by TCR will direct 
the thymocyte towards controlled apoptosis and deletion (Palmer, 2003). This process 
is also known as negative selection. An alternative to negative selection and deletion 
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is the ability of these cells to undergo TCR editing and subsequently lose their 
autoreactive TCR and become anergic (McGargill et al., 2000). Recently, a fourth 
pathway has been described detailing the development of T cells selected against high 
affinity peptides that normally induce negative selection, sometimes referred to as 
agonist selection (Baldwin et al., 2004). These cell types include NKT cells, CD8αα 
intestinal intraepithelial lymphocytes (IEL), and possibly also CD4+CD25+ 
regulatory T cells and γδ T cells. It is still unclear how the intracellular signaling and 
genetic signatures differ between those cells selected on high versus low affinity 
peptides during positive selection (Bettini and Vignali, 2010). Thus, the exact events 
and molecules that facilitate selection of nTreg cells in the thymus are still 
controversial. 
Accumulated evidence show that co-stimulatory molecules play a role in nTreg 
development. In B7 or CD28 knockout mice, or mice treated with the respective 
blocking antibodies markedly reduced numbers of nTregs in the thymus and in the 
periphery were observed (Salomon et al., 2000; Bour-Jordan et al., 2004, 2011; Tang 
et al., 2004). It was shown that CD28-deficient mice have approximately 80% 
reduction in the frequency of thymic nTreg cells (Lohr et al., 2004; Tai et al., 2005). It 
was observed that nTreg cell TCR repertoires of CD28-sufficient and CD28-deficient 
mice were not dramatically different (Lio et al., 2010). Studies using TCR-cognate 
antigen double-transgenic mouse models have supported these results (Hinterberger et 
al., 2011). Thus, it was concluded that the primary role of CD28 molecule is to 
enhance either the efficiency of nTreg cell development and/or the survival of 
thymocytes undergoing nTreg cell differentiation (Lio et al., 2010; Hinterberger et al., 
2011; Hsieh et al., 2012).  
It is considered that the development of nTreg cells occurs in two steps: CD4+ SP 
thymocytes mature into precursor nTreg cells then precursor nTregs expressing CD25 
and then into functional CD4+CD25+Foxp3+ nTreg cells (Lio and Hsieh, 2008; 
Hsieh et al., 2012). The first step of development of nTreg depends on interactions 
between distinct molecules on developing nTreg with cognate molecules expressed on 
APC, namely: TCR/MHC II and CD28/CD80 or CD86. In consequence thymic 
CD4+CD25+ Foxp3– nTreg cell precursors are generated. Second step is an IL-2-
dependent process drives thymic nTreg cell precursors to mature CD4+CD25+ 
 Foxp3+ nTreg cells (Fig. 1.4) (Tai et al., 2005; Lio and Hsieh, 2008; Lio et al., 2010; 
Klein and Jovanovic, 2011; Lu et al., 2015). In this regard, it has been shown that SP 
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subsets temporally preceded the development of Foxp3+CD25+ nTreg cells (Fontenot 
et al., 2005). In addition, it was subsequently found that the SP CD4+ subset was 
enriched in cells that developed into Foxp3+CD4+ T cells after intrathymic transfer 
(Lio and Hsieh, 2008). Notably, these nTreg cell precursors did not require further 
TCR stimulation to upregulate Foxp3, suggesting that nTreg cell differentiation could 
be divided into TCR-dependent and TCR-independent steps (Fig. 1.4) (Hsieh et al., 
2012). It was suggested, however, that TCR-independent step reflected merely a delay 
in the time between the TCR signal and the expression of Foxp3. However, short-term 
culture of the SP CD4+ subset in vitro suggested that this was not always the case, 
and that additional signals were required for the up-regulation of Foxp3.  
Studies on the role of cytokines in the development of nTregs suggested that IL-2 is 
an important player in the second step of generation of nTregs. Indeed, it was shown 
that the presence of IL-2 and to a lesser extent of IL-15 in the medium of in vitro 
cultured Foxp3–CD25+ thymocytes, was sufficient to rapidly induce Foxp3 expres-
sion (Lio and Hsieh, 2008), potentially through the binding of signal transducer and 
activator of transcription 5 (STAT5) directly to the Foxp3 locus (Zorn et al., 2007; 
Burchill et al., 2007; Yao et al., 2007; Bets et al., 2014). On the other hand, nTreg 
cells require high affinity (TCR) ligation by an agonist peptide-MHC II complex for 
Foxp3 induction (Jordan et al., 2001; Relland et al., 2009). It has been suggested that 
affinity/avidity between TCR and II MHC-peptide complex play a pivotal role in the 
nTreg cell development and selection. nTreg cell development may therefore depend 
on multiple levels of TCR–antigen interaction as elucidated in ‗niche‘ model (Hsieh et 
al., 2012). Firstly, the strength of the interaction between a TCR and an antigenic 
peptide–MHC class II complex is commonly referred to as ―affinity‖, and it 
determines the signaling from one TCR complex. Secondly, the amount of cognate 
antigen per thymic APC, in conjunction with the affinity of this antigen for the TCR, 
would affect the overall strength of TCR signaling in a single T cell. This parameter is 
known as the avidity of TCR stimulation. Thirdly, the number of thymic epithelial 
cells and dendritic cells presenting the cognate antigen and expressing co-stimulatory 
molecules at sufficient levels would determine, depending on affinity and avidity, the 
integrated TCR signal over space and time, and this may be abstractly encompassed 
by the notion of a nTreg cell developmental ‗niche‘(Hsieh et al., 2012). 
It has been suggested that the developmental signal to become nTreg cells requires 
unique interactions between the TCR and thymic stromal cells expressing class II 
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MHC–self-peptide complexes (Jordan et al., 2001; Kawahata et al., 2002). 
Furthermore, it seems that medullary thymic epithelial cells (mTECs) which express 
and present specific self-antigens in context of MHC class II molecules, support 
Foxp3+ nTreg selection (Aschenbrenner et al, 2007).  Similarly, dendritic cells (DCs) 
are thought to induce CD4+CD25+ nTregs in the human thymus through T cell 
antigen receptor (TCR)–peptide–II MHC interaction (Watanabe et al, 2005). 
However, the relative contributions of thymic dendritic and epithelial cells in 
generating and supporting the development of nTreg repertoire are not yet completely 
investigated. Actually, the cellular origin, and spatial and temporal importance of the 
signals necessary for nTreg development have not been determined yet, and, 
therefore, the rules governing how developing nTregs receive and process these 
signals are poorly understood. On the other hand, some studies have indicated that the 
development of nTreg requires co-stimulatory molecule (CD28) (Tang et al., 2003), 
high affinity self-reactive T cell receptor signals (Hsieh et al., 2006; Liston and 
Rudensky, 2007), and possibly IL-2 (Bayer et al., 2007). It has been shown that IL-2 
administration in mice increased Treg number and their suppressive function, and 
protected from chronic inflammation (Tang et al., 2008; Wilson et al., 2008; Webster 
et al., 2009; Dinh et al., 2012). 
Recent study by Goldstein and colleagues has demonstrated that a small number of 
nTreg precursors expressed pSTAT5 ex vivo in unmanipulated neonates and they 
proposed that this population may be the direct precursors of pSTAT5+ 
CD25+Foxp3+ nTregs. Albeit, not all Foxp3+ T cells express pSTAT5, suggesting 
either that Foxp3 expression can be maintained without continuous STAT5 
phosphorylation or that differentiation of nTreg may proceed through a STAT5-
independent pathway. Thus, the exact mechanism by which CD122 signaling controls 
the generation of nTregs remains to be determined (Goldstein et al., 2011). 
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Figure 1.4:— A two-step model of nTreg cell development.  
When thymocytes recognize self-peptide–MHC class II complexes in the presence of co-stimulatory 
molecules (such as CD80 or CD86) and with sufficiently high per cell avidity for regulatory T cell 
selection, some of these cells are selected as Foxp3–CD25+ nTreg cell precursors. Presumably the T 
cell receptor (TCR) signal leads to the activation of several downstream pathways, including nuclear 
factor-κB (NF-κB) activation, and results in the remodeling of the forkhead box P3 (Foxp3) locus, 
rendering it permissive to the induction of Foxp3 expression by interleukin-2 (IL-2) signaling. At this 
point, the nTreg cell precursor does not require further TCR stimulation for the expression of Foxp3. 
Instead, cytokine signals mediated by IL-2, or to a lesser extent IL-15, facilitate the induction of Foxp3 
expression (according to Hsieh et al., 2012). 
 
1.4. Role of antigen-presenting cells in the generation of Tregs 
nTregs develop in the thymus and require cooperation from other cells 
available normally or transiently in the thymus such as thymic epithelial cells, thymic 
dendritic cells or other APC-like cells (Fig. 1.5 A). Several populations of DC were 
characterized depending on location, phenotype, and function. For instance, sirpα+ 
dendritic cells (DCs), CD8α+ DCs, plasmacytoid DCs, and thymic medullary 
epithelium have been shown to contribute to thymic nTreg development (Watanabe et 
al., 2005; Wan and Flavell, 2006; Aschenbrenner et al., 2007; Proietto et al., 2008; 
Vitali, 2009; Martin-Gayo et al., 2010; Hanabuchi et al., 2010; Cowan et al., 2013; 
Coquet et al., 2013). All these subsets can capture and present antigens in the 
lymphoid organ itself and share the capacity of antigen presentation to T cells. 
However, lymphoid organ-resident DCs include most of the DCs in the thymus and 
spleen, and half of the lymph-node DCs at the steady state. 
The generation of nTregs in the thymus requires several signals which were partially 
described in the previous chapter. Strong signal from TCR and the interaction 
between key molecules, such as CD28, CD40L, GITR, and LFA-1 on T cells with 
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their respective ligands CD80/CD86, CD40, GITRL and CD54 (ICAM-1) on thymic 
stromal cells, dendritic cells, or other APCs (Malek et al., 2002; Magi et al., 2005; 
Jiang et al., 2006; Burchill et al., 2007;  Spence and Green, 2008; Vitali, 2009).The 
interactions between TCR-MHC II-self peptide, CD40-CD40L and CD28-
CD80/CD86 are known to be crucial in this process (Watanabe et al., 2005; Proietto et 
al., 2008; Spence and Green, 2008; Martin-Gayo et al., 2010; Hanabuchi et al., 2010; 
Coquet et al., 2013; Lu et al., 2015). For instance, in mice that lack either 
CD80/CD86 or CD28 a marked reduction of Foxp3+ Tregs was observed (Salomon et 
al., 2000; Tang et al., 2003; Tai et al., 2005; Vang et al., 2010). Furthermore, dendritic 
cells by capturing peripheral antigens and migrating to the thymic medulla, also play a 
distinct role in shaping the size and repertoire of thymic nTreg cells (Duncan et al., 
2002). 
Common γ-chain cytokines (i.e. IL-2, IL-15 and to a lesser degree IL-7) are required 
for thymic development of nTreg cells, as well as for their survival in the thymic 
medulla as well as in the periphery (Fig. 1.5 A).  
Several specific DC subsets were found to induce CD4+CD25+Foxp3+ Tregs from 
activated CD4+CD25–T helpers in the periphery (Apostolou and von Boehmer, 2004; 
Kretschmer et al., 2005). Due to these observations, it was assumed that DCs could be 
used for the in vitro induction of Tregs from CD4+CD25– T helpers. The induction of 
Foxp3 expression in naïve T CD4+ cell population occurs under suboptimal TCR 
signaling or by a combination of strong TCR engagement together with TGF-β or IL-
2 (Vitali, 2009).  
In addition to the thymus, Treg generation takes place in different conditions and 
locations such as in the mesenteric lymph nodes or in the gut lamina propria in the 
process of induction of oral tolerance or after tissue transplantation. There is a 
consensus in murine and human studies that the best status of DCs which can induce 
Tregs is tolerogenic DC. Generally, the tolerogenicity of DCs is governed by their co-
stimulatory setup, with low levels of co-stimulatory molecules and high levels of 
inhibitory ligands, such as PD-L1 and ILT-3/4, favoring Treg induction (Schmetterer 
et al., 2012). One line of studies revealed that the transduction of human monocyte-
derived DCs (mdDCs) with Foxp3 and co-culture of such DCs with naïve T cells led 
to the induction of Foxp3+ iTregs, which showed potent regulatory capacity in in 
vitro system (Lipscomb et al., 2010). Additionally, it was found that repeated co-
culture of ex vivo prepared immature DC with allogenic CD4+ T cells leads to up-
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regulation of CD25 on the surface of the T cells and to the acquisition of suppressive 
capacity. This new population of cells do not proliferate and is able to suppress CD4+ 
and CD8+ effector T cells proliferation (Jonuleit et al., 2000). 
 
 
Figure 1.5:— Signals for thymic and peripheral generation of Tregs.  
A/ nTreg differentiation in the thymus requires high affinity TCR engagement, CD28 binding 
and cytokine signaling. B/ In the periphery, under chronic low dose antigen stimulation, the 
presence of cytokines like TGF-β and IL-2 or other metabolites favors Treg generation 
(Vitali, 2009). 
 
The role of cytokines in the generation of iTregs has been postulated. For instance, the 
implication of TGF-β and IL-2 in the murine iTreg conversion is contrary to the 
generation of nTreg for which both TGF-β and IL-2, though important, are not 
indispensable; the lack of TGF-β signaling is rapidly counterbalanced by higher IL-2 
production (Liu et al., 2008), while IL-2 deficiency is supplemented by IL-15 (Vitali, 
2009) (Fig. 1.5 B). Moreover, the endogenous TGF-β produced by CD4+CD25+ 
Foxp3+ Treg cells enables IL-6 to convert some of these cells to Th17 cells (Xu et al., 
2007; Dons et al., 2012). 
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On the other hand, neutralization of IL-2 during iTreg induction abolished the 
development of suppressive function, while iTreg induction using allo-stimulated 
CD4+CD25– T cells required IL-2 and TGF-β (Zheng et al., 2007). 
CTLA-4 is also involved in the generation of Tregs in the periphery as was observed 
in CTLA-4-deficient murine T cells that could not differentiate into iTregs. The role 
of TGF-β in this case is to induce or accelerate the expression of CTLA-4 during T-
cell activation and in consequence induce the expression of Foxp3 after CD80 or 
CD86 binding. In contrast, Foxp3 expression plays a role in the up-regulation of 
CTLA-4 expression (Zheng et al., 2006). 
Finally, the cooperation between DCs and CD4+ T cells in peripheral lymphoid 
organs or thymus to generate iTregs and nTregs respectively, depends on several 
factors such as the level of maturation of DCs or T cells, the array of cytokines 
available in the microenvironment, and the expression of co-stimulatory molecules on 
the surface of interacting cells.  
1.5. Role of B cells in the induction of Tregs in the thymus and peripheral 
lymphoid organs 
 It has been found that B cells can take part in antigen presentation via MHC II 
molecules that are constitutively expressed on their membrane and are rapidly up-
regulated upon activation (Germain and Jenkins, 2004; Byersdorfer et al., 2004; 
Rodriguez-Pinto and Moreno, 2005). In addition to their function as APCs, B cells 
exert multiple functions in adaptive immunity, for instance, antibody secretion and 
germinal center (GC) formation, and are critical cellular adjuvants that facilitate 
optimal activation of CD4+ T cell. B cells also contribute to immunoregulation due to 
production of cytokines including IL-4, IL-6, IL-10, IFN-γ, and TGF-β. In addition, B 
cells are thought to have specific roles in stimulating Ag-specific CD4+ T-cell 
proliferation after activation by DCs. However, their role in generation of nTregs is 
poorly understood as well as the immunological outcome of B cell-mediated antigen 
presentation has been a subject of debate, and data in this regards is limited. For 
instance, B cells can efficiently generate Tregs in vitro (Reichardt  et al., 2007; Chen 
et al., 2009; Zheng et al., 2010; Lu et al., 2015), in contrast, they were reported to 
induce deletion of self-reactive T cells in vivo (Frommer et al., 2008). Thus, the role 
of B cells in the induction of T-cell tolerance to self-antigens under physiologic 
conditions, and in particular, in the induction of nTregs, remains to be determined. 
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1.5.1. Role of peripheral B cells in the induction of peripherally-derived Tregs 
Direct effect of B cells on iTreg induction in peripheral lymphoid organs can 
be seen in in vitro experiments in B cells co-cultivated with naïve Treg. Splenic B 
cells comprise different subsets, and about 80% of them are resting, mature B2 cells 
(Hsueh et al., 2002). Several molecular interactions between the interacting cells are 
possible. By using knockout mice or receptor blockade with CTLA-4 
immunoglobulin, it was shown that both CD28/B7 and CD40/CD40L interactions are 
important in iTreg development, as CTLA-4 depletion led to decrease in 
CD4+CD25+ T cell number and accelerated autoimmunity in autoimmune-prone 
backgrounds (Salomon et al., 2000; Kumanogoh et al., 2001). It has not been 
absolutely confirmed, however, whether such molecules act solely at the level of 
thymic nTregs generation or also affect peripheral iTregs induction, homeostasis 
and/or survival. Moreover, several groups have demonstrated that strong co-
stimulation provided by B7 through CD28 during iTreg generation prevents Foxp3 
up-regulation and renders cells with poor suppressive function (Fu et al., 2004; 
Benson et al., 2007; Molinero et al., 2011). 
The role of other molecules in the generation of Tregs has also been studied. It has 
been found that OX40/OX40L, an alternative, CD28/B7-independent co-stimulatory 
pathway, also negatively regulates the development and function of both iTregs and 
nTregs. While stimulation of mature nTregs by OX40 results in the loss of 
suppression of T cell proliferation and cytokine production, the generation of iTregs is 
completely abolished by OX40, although OX40 does not affect the generation of 
nTregs (So and Croft, 2007). 
In non-Hodgkin lymphoma mice, the number of Foxp3+ regulatory T cells is greatly 
increased within the tumor. This increase was critically dependent on the presence of 
CD70+ B cells. Additionally, removal of CD70+ B cells or blockade of the CD70 
molecules, inhibited the intratumoral generation of iTreg. This result indicates that B 
cells, via interaction of the CD70/CD27 molecules are able to induce iTreg in vivo 
(Yang et al., 2007). On the other hand, it was documented that B cell-induced iTreg 
are crucial for the cure of the EAE (Experimental autoimmune encephalomyelitis). 
While wild type mice recover from EAE spontaneously, B cell deficient µMT mice 
suffer from the disease. Analysis of the affected animals revealed lack of iTreg and 
IL-10 in the central nervous system. After administration of wild type B cells iTreg 
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numbers normalized and then the animals recovered from the EAE (Mann et al., 
2007). These effects were critically dependent on the expression of B7 molecules by 
B cells indicating that stimulation of the iTreg via CD28 pathway is critical for their 
induction in such conditions. 
To document the impact of B cell-mediated induction of iTregs, Chen and Jensen 
used B cells and DCs from B6 spleens (APCs) and co-cultured them with total splenic 
CD4+ T cells as responder cells after depleting other type of cells. The authors have 
found that primary culture of BALB/c spleen CD4+ T cells contained 8–15% of 
Foxp3+ T cells, and after culture with B6 B cells, this percentage was increased to 
31–47% in independent experiments. If DCs served as APCs this ratio was 0.08–0.19. 
These results indicated clearly that although B cells are less potent than DCs in 
allostimulation, primary B cells preferentially induced the generation of allogeneic 
Foxp3+ T cells (Chen and Jensen, 2007). Furthermore, in addition to their role in the 
generation of iTregs, recent evidence has shown that B cells are capable of expanding 
iTregs in the presence of co-stimulatory molecules plus IL-2 (Chen and Jensen, 2007; 
Chen et al., 2009). In addition, Moore and colleagues (2010) have investigated the 
cooperation between B cells and DCs in the generation of iTregs in the presence of 
TGF-β, RA (Retinoic Acid), and IL-2. Isolated B-cells were co-cultured with naïve T 
cells in the presence of these three factors at a 1:7 ratio of B to T cells. It was found 
that B cells alone were not as efficient for the generation of iTregs as partially 
purified CD11c enriched APCs. Additionally, isolated B cells induced higher 
proportion of iTregs in the absence of cytokines in comparison to partially purified 
APC fraction, concluding that optimal iTreg induction occurs when both populations 
of APCs are present (Moore et al., 2010). The mechanism by which RA enhances 
Foxp3 expression and increases suppressive capacity in iTreg remains controversial. 
Several lines of results have demonstrated that RA functions either through a 
cytokine-dependent mechanism, by blocking the secretion of proinflammatory 
cytokines by memory T cells (Hill et al., 2008), or through cytokine-independent 
mechanisms, because RA retains its inhibitory effect in the absence of cytokines 
(Nolting et al., 2009). 
It was shown that B cell and F4/80
+
 ocular APC act together as inducers of Treg in 
the anterior chamber associated immune deviation model (Ashour and Niederkorn, 
2006). In this study antigens introduced into the anterior chamber of the eye are 
transported by F4/80
+
 ocular APC to the spleen where the antigen is released and 
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picked up by B cells. Eventually, these B cells present the antigens in context of MHC 
II and MHC I simultaneously, giving rise to CD4+ and CD8+ Tregs respectively. 
Collectively, the implication of B cells in the induction of iTregs both in vivo and in 
vitro needs more investigations. Also, many questions still require elucidation, such as 
1/ What population of B cells and at which maturation stage can induce optimal 
number of nTregs? 2/ Which B cell molecules have a dominant role in this process? 3/ 
Are there any other factors that can facilitate and accelerate the generation of nTregs 
by B cells, for instance cytokines?  
1.5.2. Thymic B cells and their role in the development of thymus-derived Tregs 
Recently several studies have shed a light on the role of B cells in the 
generation of nTregs, and many of these studies has been focused on thymic B cells. 
B cells can play a role of APC because of their constitutive high expression of MHC 
II and the ability to uptake, process, and present antigens to CD4+ T cells via B cell-
mediated mechanism. Additionally, B cells constitutively express co-stimulatory 
molecules such as CD80 and CD86 as well as CD40, and their expression increase 
upon activation. These molecules, as it was described for dendritic cells, have an 
important role in the generation of nTregs (Watanabe et al., 2005; Proietto et al., 
2008; Spence and Green, 2008; Martin-Gayo et al., 2010; Hanabuchi et al., 2010; 
Walters et al., 2014; Lu et al., 2015).  
The thymus contains low number of B cells (about 0.1–0.5% of total population of 
thymocytes) that were shown to contribute in thymic negative selection (Frommer and 
Waisman, 2010; Perera et al., 2013). Evidence that B cells can play a role in T cell 
selection process in the thymus has emerged from rodent studies examining minor 
lymphocyte-stimulating (Mls) Ags (von Boehmer and Sprent, 1974). The results have 
indicated that clones reactive to specific Mls Ags, such as T cells bearing the Vβ6 
TCR element reactive for Mls-1a, are deleted by thymic B cells (Mazda et al., 1991; 
Gollob and Palmer, 1993; Tuama et al., 2000). Further studies have extended this 
concept to other model of Ags (Kleindienst et al., 2000; Frommer and Waisman, 
2010) demonstrating that B cells can contribute to shaping of thymic T cell repertoire 
through negative selection.  
Thymic B cells exist in the thymus during early fetal development and reach stable 
frequency after birth that is further maintained throughout the life (Marcos et al., 
1989; Nango et al., 1991). However, the fact that B cells in the periphery have been 
involved in the generation of the Treg compartment (Wei et al., 2005; Zheng et al., 
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2010; Morlacchi et al., 2011; Ray et al., 2012), suggested that this process may indeed 
be initiated firstly within the thymus. Using an in vitro culture model, Lu and 
colleagues (2015) have revealed that thymic B cells have important role in regulating 
the size of the nTreg compartment in the thymus. It was demonstrated that thymic B 
cells are localized in the thymic medulla in close proximity to nTreg precursors, 
particularly around Hassall‘s corpuscles, but also in the perivascular and intralobular 
spaces (Isaacson et al., 1987; Christensson et al., 1988; Walters et al., 2014; Lu et al., 
2015). In addition, thymic B cells deficiency results in a significant decrease in both 
the frequency and number of thymic nTreg cells. Further, it has demonstrated that 
thymic B cells contribute to thymic nTreg cell number via cell-cell contact involving 
two independent pathways. In the first step, thymic B cells promote the generation of 
thymic nTreg precursors from CD4+ SP subsets. Then thymic B cells directly 
promote the proliferation of thymic nTreg cells both in vivo and in vitro that is MHC 
II contact dependent and an intact BCR repertoire (Walters et al., 2014) with fewer 
contribution of the co-stimulatory molecules CD40/CD80/CD86. Thus signals 
required for thymic nTreg development may be distinct from those required for 
thymic nTreg proliferation (Lu et al., 2015). 
In addition to the above mentioned functions of thymic B cells, these cells are directly 
implicated in the induction of tolerance in the thymus (Ashour and Seif, 2007). In this 
regard, studying the mechanisms and cells responsible for the development of 
tolerance may improve the treatment of allergic diseases, autoimmune diseases, help 
to prevent transplant rejection, and the development of an immune response during 
gene therapy. It was suggested that B cells play a role in negative selection of 
CD4+CD8– SP but not CD8+CD4– SP thymocytes (Frommer and Waisman, 2010). 
Though activation of T cells by B cells as APC requires co-stimulation, resting B cells 
with low expression of B7 induce T cells tolerance (anergy). In vivo, dendritic cells 
can prevent such induced anergy by providing additional co-stimulatory signals 
(OX40L, cytokines) (Lohr et al., 2005; Huddleston et al., 2006). 
T cell precursors expressing high-affinity receptors for MHC-self peptide complexes 
are eliminated. The regulator protein Aire (autoimmune regulator) plays a key role in 
this process. It is a transcription factor that enables the thymic cells to produce their 
full arsenal of endogenous proteins. Recently, it has been discovered that B cells 
migrating into the thymus also contribute to central tolerance. On entering the thymus, 
they alter their molecular profile and become more efficient in tolerance induction. 
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These B cells migrating into the thymus (but not peripheral B cells) also express Aire 
and can efficiently induce T cell-tolerance (Yamano et al., 2015a). In the same study, 
it was shown that Aire expression in thymic B cells coincided with MHC II and CD80 
up-regulation and immunoglobulin class-switching. These features were recapitulated 
upon immigration of naïve peripheral B cells into the thymus, whereby this 
intrathymic licensing required CD40 signaling in the context of cognate interactions 
with autoreactive CD4+ thymocytes. Moreover, a licensing-dependent neo-antigen 
selectively up-regulated in immigrating B cells mediated negative selection through 
direct presentation (Yamano et al., 2015a).   
Several studies have indicated the role of different molecules involved in the 
induction of T cell tolerance. However, the role of each molecule in achieving 
tolerance still requires further elucidation. MHC II and B7 (CD80/CD86) molecules 
were suggested to play an important role in tolerance development. The mechanistic 
studies have shown that transduced B cells must express MHC II and B7.2 (CD86) 
co-stimulatory molecules for successful tolerance induction (El-Amine et al., 2000; 
Litzinger et al., 2005). CD80 and CD86 molecules on APC interact with CD28 and 
CTLA-4 on T cells to transduce co-stimulatory signals (Jordan et al., 2001; Levings et 
al., 2005). After transient blockade of B7/CD28 co-stimulation by monoclonal 
antibodies prolonged allograft survival in rodent models is observed (Fowell and 
Mason, 1993). Other results have revealed that exposure to intra-nasal prototypic 
protein antigens was associated with rapid partial activation of antigen-specific B 
cells, characterized by increased expression of MHC II and co-stimulatory molecules. 
In the absence of B cells, respiratory tolerance could not be induced (Tsitoura et al., 
2002).  
Recently, anti-CD154 has been investigated as a new strategy for elongating allograft 
tolerance. In in vivo studies, allogeneic C57BL/6 hearts were rejected in 9 days when 
transplanted into untreated BALB/c recipients, while treatment with anti-CD154/DST 
(donor-specific transfusion) induced long-term allograft survival. This data suggested 
that the alloreactive-specific B cell responses are inhibited by regulatory T cells acting 
to constrain T cell help (Li et al., 2007; 2008). Other authors argued that anti-CD154 
treatment could suppress B cell responses, but is not able to induce B cell tolerance 
(Foy et al., 1993). It was shown in another allograft model of tolerance induced by 
blockade of CD40/CD154 co-stimulation that recruitment of Foxp3+ Treg cells to 
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allograft tissue depends on the expression of the chemokine receptor, CCR4 (Lee et 
al., 2005). Studies performed in CD40L-deficient and MHC class II-deficient patients 
revealed that antibody reactivity of new emigrant B cells was similar to those from 
healthy donors, suggesting that CD40/CD40L interactions and antigen presentation do 
not regulate central tolerance. In contrast, mature naïve B cells from CD40L-deficient 
and MHC class II-deficient patients produced high percentage of auto-reactive 
antibodies (Herve et al., 2007).  
1.6. The aim of the study 
We hypothesized that B cells can be involved in the generation of thymus-
derived regulatory T cells. Our hypothesis was built on the following observations. 
Firstly, normal development of nTreg in the thymus requires interaction with thymic 
antigen-presenting cells such as dendritic cells and thymic epithelial cells. These cells 
present self-antigens to developing nTreg allowing their selection and maturation. 
Secondly, very small percentage of B cells reside in the thymus, and their function 
and origin are still controversial. Thus, we decided to investigate if B cells, which can 
play a role of antigen-presenting cells for peptide antigens (Vascotto et al., 2007; 
Taneja et al., 2007; Roux and Niedergang, 2012), have the potential to induce the 
generation of thymus-derived regulatory T cells in vitro.  
We introduced a model of co-culture of thymocytes with splenic B cells based on the 
results of Bieńkowska et al. (Bieńkowska et al., 2014) on the role of different sources 
of activatory signals necessary to the generation of thymic Tregs. Our model utilized 
splenic B cells as it was shown that peripheral B cells are able to migrate into the 
thymus (Yamano et al., 2015a). Thymocytes served as the source of nTregs 
precursors. We investigated the role of B cell stimulation by TLR ligands on the 
antigen presenting potential and its influence on nTreg generation. 
Lipopolysaccharide of Gram-negative bacteria (LPS) and imiquimod (IMQ) have 
been used as TLR4 and TLR7 ligands simulating infections by bacteria and viruses, 
respectively. We postulate that depending on the level of MHC II and CD80/CD86/ 
CD40 molecules expression, B cells can induce the differentiation of thymus-derived 
regulatory T cells.   
To confirm this hypothesis the following issues were investigated: 
 1. Antigen-presenting potential of B cells activated by LPS and IMQ. 
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2. Potential of splenic B cells to generate nTreg cells in vitro. 
3. Potential of thymic B cells to generate nTreg cells in vitro (preliminary study). 
In addition, considering the influence of glucocorticosteroids on dendritic cells we 
have examined the role of these hormones in the induction of tolerogenic potential of 
activated B cells. 
1.7. Study outline 
1. To evaluate the antigen-presenting potential of splenic B cells the expression of 
MHC II, CD80, CD86, and CD40 was estimated after LPS or IMQ stimulation. 
2. To examine the potential of B cells to induce the generation of natural regulatory 
T cells in vitro model of co-culture of thymocytes with splenic B cells was 
utilized. The model was based on two-step process of nTreg development: firstly 
TCR signal was delivered by B cells themselves or by anti-CD3 monoclonal 
antibodies, and next the co-stimulatory signal was delivered by activated B cells.  
3. The suppressive function of nTregs isolated from the co-culture of thymocytes 
and activated B cells was evaluated in the biological assay. 
4. The role of co-stimulatory molecules expressed by B cells was evaluated using 
blockade strategy. 
5. The generation of nTregs in the co-culture of thymocytes and B cells was 
examined based on the distribution of the main thymocyte subsets, CD25 and 
Foxp3 expression. 
6. The role of thymic B cells in nTreg generation was examined in cultures of 
thymic cells in LPS or IMQ-conditioned culture. 
7. The role of glucocorticoids on nTreg generation was investigated in the co-
cultures of thymocytes and activated B cells. 
 
 
 
 
 - 52 - 
2. Materials and Methods 
2.1. Mice 
8–12 weeks old B6.Cg-Foxp3tm2Tch male mice (expressing Foxp3 protein in co-
expression of GFP protein), as well as 8-10 weeks old male C57BL/6 mice were used 
in experiments. Mice were bred and maintained in the Animal Facility at the Faculty 
of Biology, University of Warsaw in the individually ventilated cages system (IVC) 
LD (light/dark) 12/12 h, with free access to standard food and water. All the 
procedures involving animal studies have been approved by the Local Ethic 
Commission under permission number 30/WB/2010.  
2.2. B cell purification 
The mice were sacrificed in CO2 chambers. Freshly isolated spleens were 
placed into cold PBS and immediately homogenized. The cells were filtered through 
50 µm cell strainer (Becton-Dickinson) to remove tissue debris. The cells isolated 
from organs were counted and a suspension of cells in PBS at the appropriate density 
was prepared for further analysis. The viability of the cells was determined by 
staining with 0.4% trypan blue solution. B cells were obtained by depletion of T cells 
using anti-Thy-1 coated (CD90.1) microbeads by magnetic cell sorter (MACS, 
Miltenyi Biotec). Briefly, splenic cells were washed 1 time with PBS and red blood 
cells (RBCs) were lysed using RBC lysing solution. After RBCs lysis, the splenic 
cells were washed twice with PBS. B cell separation was performed according to the 
manufacturer‘s procedure. In brief, splenic cells were suspended in MACS buffer (107 
cells/90 µl of the buffer), and 10 µl of anti-Thy-1 coated beads were added. The 
mixture was incubated 15 min at 4
o
C. After the incubation, the cells were washed 
twice with MACS buffer. Finally, the cell suspension was sorted using MACS 
instrument according to the manufacturer‘s instructions. The purity of splenic B cells 
was > 96%, as assessed by flow cytometry by staining with anti-CD3 monoclonal 
antibodies conjugated with PE and anti-CD19 MoAb conjugated with APC. The 
purified B cells were resuspended in culture medium for all further in vitro cultures. 
2.3. Cell culture conditions   
For the in vitro cell cultures RPMI-1640 Glutamax medium (Gibco)  
supplemented with antibiotics (Penicillin 50 mU/ml and Streptomycin 50 ng/ml) 
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(Gibco), 10% fetal bovine serum (Gibco), 1 mM sodium pyruvate (Gibco), and 0.2 
mM 2-mercaptoethanol (Gibco) was used. Thymocytes and B cells were cultured at 
37ºC in a 5% CO2 humidified atmosphere for 24 and 72 h. 
To characterize the expression of MHC II and co-stimulatory molecules on B cells, 
splenic cells were cultured in flat-bottom 24-well plates in LPS or IMQ-conditioned 
medium. Non-activated splenic cells served as control. 
To investigate the role of B cells in the generation of nTreg cells thymocytes were co-
cultured with isolated splenic B cells. Thymocytes at the density of 2 × 10
6
 cells/ml 
and B cells were co-cultured in 10:1 and 1:1 ratio in  flat-bottom 24-well plates. 
The following culture conditions were applied:  
- Co-culture of thymocytes with non-activated and activated isolated splenic B 
cells was performed. LPS from Escherichia coli (0111:B4) (SIGMA) (1 µg/ml 
and 0.01 µg/ml) and imiquimod, IMQ, (SIGMA) (5 µg/ml and 1 µg/ml) were 
used to activate B cells. The concentrations were chosen according to (Xu et 
al., 2008), and (Sauder, 2000), respectively. 
- The control samples consisted either from non-activated thymocytes culture 
alone to compare with co-cultures or non-activated splenocytes culture alone 
to compare with activated splenocytes. 
- Co-cultures of anti-CD3 pre-activated thymocytes with non-activated and 
isolated activated splenic B cells were performed. The plate was coated with 
anti-CD3 monoclonal antibodies (BD Pharmingen) (5 µg/ml) according to 
(Bieńkowska et al., 2014). Next the thymocytes were cultured 24 h on anti-
CD3 pre-treated plates before addition of B cells. Anti-CD3 pre-activated 
thymocytes served as a control. 
- Co-cultures of thymocytes with activated B cells in the presence of Dex (10-8 
to 10
-12
 M) were performed.   
2.4. Flow cytometry analysis of B cell markers 
To analyze the expression of MHC II and co-stimulatory molecules (CD80, 
CD86, CD40) on B cells, the following monoclonal antibodies were used: anti-
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CD19/APC (clone 1D3), anti-CD80/PE (clone 16-10A1), anti-CD86/PE (clone GL1), 
anti-CD40/PE (clone 3/23), and anti-MHC II/PE (clone M5/114.15.2), all reagents 
have been purchased from BD Pharmingen. B cell staining was performed according 
to standard procedure. The gating strategy to analyze B cell markers is presented in 
Fig. 2.1. 
 
Figure 2.1:— Gating strategy of splenic B cells.  
A/  Whole population of splenocytes (R1), B/  CD19+ B cells have been gated (R2), C/  CD19+ living 
B cells have been gated (R3). Percentage of living-splenic B cells positive for CD80 (D), CD86 (E), 
CD40 (F), and MHC II (G) molecules has been analyzed. 
2.5. Flow cytometry analysis of thymus-derived Treg generation in the co-culture 
with B cells  
Thymocytes are classified into four main subsets according to the expression 
of CD4 and CD8 molecules: CD4−CD8− (double negative: DN), CD4+CD8+ (double 
positive: DP), CD4+CD8−, and CD8+CD4− (single positive: SP). Natural regulatory 
T cells (nTregs) are recognized as CD4+Foxp3+ within SP CD4+CD8− thymocytes 
or as CD4+CD25+Foxp3+ in the same thymocyte subset (SP CD4+CD8–). 
B cells co-cultured with thymocytes were determined basing on the expression of 
CD19. 
For thymocyte staining the following monoclonal antibodies were used: anti-
CD4/PerCP (clone RM4-5) or PE (clone H129.19), anti-CD8a/PE (clone 53-6.7) or 
APC (clone 53-6.7) or PerCP (clone 53-6.7), anti-CD25/APC (clone PC61) or PE-
Cy
TM
7 (clone PC61), and Foxp3/FITC (Foxp3 co-expressed with GFP protein), all 
reagents have been purchased from BD Pharmingen. 
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The staining has been performed according to standard procedure. In brief, 
lymphocytes were suspended in cell wash supplemented with 0.5 % BSA (bovine 
serum albumin) at 2 × 10
7
 /ml density (1milion cells per 50µl). 50µl aliquots of cells 
suspension were transferred to FACS tubes. Suitable monoclonal antibodies 
conjugated with fluorochromes were added to each sample and incubated 
(temperature 4°C, 30 minutes, in dark). After incubation, the thymocytes were washed 
twice with PBS, and the expression of markers was determined based on the 
fluorescence emission by antibodies conjugated to fluorochromes. Flow cytometry 
analysis was performed on a FACSCalibur or FACSVerse (BD Bioscience). The 
results were analyzed using CELL Quest or FACSuite/FACSDiva. The distribution of 
thymocytes populations was expressed as percentages. 
The gating strategy to analyze the generation of nTregs is presented in Fig. 2.2. 
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Figure 2.2:— Gating strategy and phenotype analysis of in vitro generated CD4+CD25+Foxp3+ 
nTregs in co-cultured with splenic B cells.  
A/  Whole population of cells (R1), B/  The percentage of SP CD4+ thymocytes have been gated for 
further analysis (R2), C/  Gated SP CD4+ thymocytes have been analyzed for CD25+ expression (R3), 
D/  Gated CD4+CD25+ thymocytes have been analyzed for Foxp3 expression. From (E) to (H) 
represented gating strategy and phenotype analysis of in vitro generated CD4+Foxp3+ nTregs in co-
cultured with splenic B cells. Whole population of cells R1 (A). To perform further analysis on nTregs 
only, CD19+ B cells have been excluded (R2) (E), and to be sure that B cells have been excluded from 
further analysis (population in R2 were excluded from further analysis) (F). SP CD4+ cells have been 
gated (R3) for further analysis (G). Gated CD4+ thymocytes have been analyzed for Foxp3 expression, 
CD4+Foxp3+ (H). 
 
 2.6. Estimation of cell viability and proliferation 
The viability and proliferation of CD4+CD25+Foxp3+ (nTregs) cells in co-
culture, were measured after 72 h using FACSVerse (BD Pharmingen). To determine 
cell proliferation Violet Proliferation Dye 450 (VPD450) was used and 7-Amino-
Actinomycin D (7-AAD) was used to assess cell viability. Both dyes were purchased 
from BD Pharmingen.  
The percentages of apoptotic DN, DP, and SP thymocytes as well as splenic B cells 
were measured by FACSCalibur using Annexin V/PE (BD Pharmingen). To 
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discriminate between living and dead splenic B cells, Annexin V/FITC was used to 
exclude dead cells from the analysis (Fig. 2.1 C).   
The level of apoptosis was determined in the main subsets of thymocytes and the 
population of nTreg. Staining of the cells was carried out in two stages:  
1/ Surface markers labeling using anti-CD4/PerCP, anti-CD8/PE, and anti-CD25/APC 
antibodies; 2/ Apoptosis analysis using Annexin V conjugated to phycoerythrin - PE 
(Annexin V-PE Apoptosis Detection Kit, BD Pharmingen) at a concentration of 0.5 
µg in stock /10
6
 thymocytes. The samples were incubated in the dark for 15 min. at 
room temperature. The results were analyzed by the CellQuest program on 
FACSCalibur cytometer. 
2.7. Determination of the suppressive activity of thymus-derived Tregs in the 
assay of inhibition of proliferation of activated-responder T cells 
Thymus-derived Tregs were sorted from 24 h co-cultures with splenic B cells. 
For nTreg sorting thymocytes were labeled with the following monoclonal antibodies: 
anti-CD4/PE, anti-CD8/PerCP, anti-CD25/PE-Cy
TM
7, and subsequently CD4+CD25+ 
nTreg cells were sorted using FACSAria (Fig. 2.3).  
Responder T cells were isolated from axillary lymph nodes and suspended at 2.5 × 
10
5
 cells/ml in complete medium (10% FBS, 2-ME, Hepes 1M, Penicillin/ 
Streptomycin, RPMI 1640 Glutamax-I, Gibco). Anti-CD3 (0.5 µg/ml) and anti-CD28 
(0.05 µg/ml) monoclonal antibodies (BD Pharmingen) were used for responder T cell 
activation. Proliferation rate was measured by staining the responder T cells with the 
fluorescent dye CFSE (carboxyfluorescein diacetate succinimidyl ester) (Lyons, 2000; 
Hawkins et al., 2007; Quah et al., 2007). Labeling was performed using Cell Trace 
CFSE Cell Proliferation Kit (Invitrogen) according to manufacturer's instructions. In 
brief, suspensions of lymphocytes isolated from lymph nodes in PBS supplemented 
with 0.1 % BSA were prepared. Suspension density of each sample was 2 × 10
7
/ml. 
10µM solution of CFSE in PBS supplemented with 0.1% BSA was prepared. The 
same volumes of cell suspensions and CFSE solution were mixed and incubated for 
10 minutes, temp. 37°C. After 1 minute cells were washed twice with medium. Cell 
suspension at the density 2 × 10
6
 /ml was used in further experiments.  
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Figure 2.3:—Schematic diagram of nTreg cell sorting.  
The labeled thymocytes: A/  Identified thymocyte population (P1); B/  T cell population of CD4 + (P2); 
C/ SP population of CD4+ thymocytes with CD25 expression (P3) was isolated; CD4+CD25− 
population was excluded (P4). 
 
 
In order to determine the suppressive activity of nTregs isolated from 24 h co-culture 
of thymocytes with splenic B cells, the following types of cultures were performed: 
1/ negative control – non-activated responder lymph node T cells; 2/ positive control 
(proliferation control) – responder T cells activated with anti-CD3 and anti-CD28 
monoclonal antibodies; 3/ co-culture of responder T cells and nTregs. Responder T 
cells were cultured with nTregs in 5:1 ratio (25×10
3
 / 5×10
3
 cells/ml). The cells were 
cultured in 96-well round bottom plate in a final volume of 200μl and incubated at 
37°C and 5% CO2. The proliferation rate of responder T cells was analyzed using a 
FACSCalibur flow cytometer (BD Bioscience) after 72 h, and the analysis was 
performed using CellQuest software.  
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nTreg suppressor activity was presented as the percentage inhibition of proliferation 
calculated according to the following equation (Bollinger et al., 2009): 
                                 % of proliferation of responder T cells with nTregs 
  inhibition = 100   × 100 
                                     % of proliferation of responder T cells 
 
2.8. Statistical analysis 
All experiments have been repeated at least in 3 independent times. The 
results are expressed as means ± SD. Data were analyzed using ANOVA from SPSS 
program (version 23) for percentage of cells, and unpaired, Student‘s t test for MFI 
(Mean Fluorescent Intensity). The significance values were indicated as▲ between 
control (non-activated) and activated cells in 24 or 72 h cultures, ● between the 
concentrations of LPS or IMQ for the same time of culture, and * between 24 and 72 
h cultures. The probability levels were indicated as follows (*p < 0.05; **p < 0.01; 
***p < 0.001; and ****p < 0.0001, and similarly for other symbols). 
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3. Results and Discussion 
 The results of this dissertation were divided into three sections:- 
1. Role of splenic B cells in thymus-derived regulatory T cell development. 
2. Thymic B cells in the development of nTregs: preliminary studies. 
3. Effect of dexamethasone on the generation of nTregs in co-cultures of 
thymocytes and splenic B cells. 
 
3.1. Role of peripheral B cells in thymus-derived regulatory T cell development 
 B cells are antigen presenting cells and can be involved in T cell activation 
and development of an immune response or the induction of tolerance by the 
differentiation of regulatory T cells that can inhibit the immune response by various 
mechanisms. B cells are considered as professional antigen presenting cells due to the 
constitutive expression of MHC II molecules, and ability to process the antigens 
endocytosed after binding with BCR. The result of antigen presentation was 
controversial as it was shown that, under certain conditions, B cells are tolerogenic 
rather than immunogenic (Fillatreau et al., 2002; Raimondi et al., 2006). Upon 
activation via TLR ligands, B cells rapidly up-regulate molecules important in B-T 
interaction including MHC II, CD80, CD86, and CD40 (Xu et al., 2008; Hanten et al., 
2008; Hua and Hou, 2013). In this section we focused on the evaluation of: 
-  the potential of LPS- and IMQ-activated B cells to present antigens as 
measured by the expression of MHC II and co-stimulatory molecules 
important in the interaction of B cells with T helper cells:   
- the potential of activated B cells to induce the development of nTregs in the in 
vitro model of co-culture of thymocytes and splenic B cells: 
- the possible mechanism of nTreg generation: 
- the suppressive activity of nTregs generated in vitro. 
TLRs signaling is important in B-cell activation and maturation (Isaza-Correa et al., 
2014). Naïve murine B cells express a repertoire of TLRs and proliferate in vitro in 
response to TLR ligands including TLR4 and TLR7 (Gray et al., 2007; Barr et al., 
2007; Hwang et al., 2009). TLR-induced signaling increase the expression of 
molecules involved in B-cell mediated activation and differentiation of CD4+ T cells. 
We analyzed the role of TLR4 and TLR7 ligands (LPS and IMQ respectively) in the 
activation of B cells as measured by the expression of molecules important for their 
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antigen-presenting potential, and we examined the potential of such activated B cells 
to induce the generation of nTregs according to the two-step model of nTreg 
development involving signals both from TCR and co-stimulatory molecules. 
3.1.1. Expression of co-stimulatory molecules and MHC II on splenic B cells 
upon activation by LPS and IMQ 
The results of our studies showed that LPS and IMQ stimulation increased the 
percentage of CD80 positive splenic B cells (Fig. 3.1 A). The effect depended on the 
LPS concentration, but did not depend on the duration of culture for the same 
concentration used. The increase of the percentage of CD80+ B cells induced by IMQ 
was not dose- or culture duration-dependent. The only exception was 1 g/ml dose 
that resulted in decrease in the percentage after 72 h of culture compared to 24 h. LPS 
and IMQ stimulation increased the percentage of CD86+ B cells (Fig. 3.1 B).  
In LPS-stimulated cultures the increase of the percentage was concentration-
dependent, but culture duration-independent. IMQ stimulation-induced the increase of 
the percentage of CD86+ B cells which did not depend on the concentration used nor 
the duration of the culture. The percentage of CD40+ B cells was not changed by LPS 
or IMQ stimulation in 24 h culture, and was maintained at the 24 h control level after 
72 h of culture (Fig. 3.1 C). LPS and IMQ stimulation did not influence the 
percentage of MHC II+ B cells (Fig. 3.1 D). 
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Figure 3.1:— Effect of LPS and IMQ on the percentage of B cells expressing co-stimulatory 
molecules. 
 CD80 (A), CD86 (B), CD40 (C), and MHC II (D) in vitro. The experiments have been performed in 
triplicates. The cells were analyzed after 24 (white bars) and 72 (black bars) hours of in vitro culture. 
The significance values were indicated as▲ between Control (non-activated) and activated B cells in 
24 or 72 h cultures, ● between the concentrations of LPS or IMQ for the same time of culture, and * 
between 24 and 72 h cultures. Control (non-activated cells), LPS1 (1µg/ml), LPS0.01 (0.01µg/ml), 
IMQ5 (5µg/ml), and IMQ1 (1µg/ml). The levels of probability were indicated as follows (*p < 0.05; 
**p < 0.01; ***p < 0.001; and ****p < 0.0001, and similarly for other symbols). 
 
Next, the expression of CD80, CD86, CD40, and MHC II molecules on splenic B 
cells was investigated. Figure 3.2 shows the surface expression of CD80, CD86, 
CD40, and MHC II on splenic B cells in 24 and 72 h of culture. The expression of 
CD80 was not changed upon LPS activation, but was increased in 24 h cultures and 
decreased in 72 h cultures upon IMQ stimulation (however, the decrease was not 
statistically significant). In IMQ-stimulated cultures up-regulation of CD80 in 24 h 
cultures and its down-regulation in 72 h cultures were not dose-dependent (Fig. 3.2 
A).  
The expression of CD86 increased upon activation by LPS and IMQ compared to 
control, and was both concentration and duration-dependent. The expression of CD86 
showed a significant increase upon activation and for all activator concentrations (Fig. 
3.2 B). The expression of CD40 and MHC II increased upon activation with LPS and 
IMQ, and was concentration and duration-dependent for CD40 (both activators) and 
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MHC II (LPS only). The expression of CD40 and MHC II increased in 72 h cultures 
compared to 24 h cultures (after activation with IMQ 5 µg/ml) however, the increase 
was not statistically significant (Fig. 3.2 C and D). 
A                                                            B 
      
C                                                              D 
          
 
 Figure 3.2:— The expression of co-stimulatory molecules. 
 CD80 (A); CD86 (B); CD40 (C); and MHC II (D) on LPS- and IMQ-activated B cells. The 
experiments have been performed in triplicates. The cells were analyzed after 24 (white bars) and 72 
(black bars) hours of in vitro culture. The significance values were indicated as▲ between Control 
(non-activated) and activated B cells in 24 or 72 h cultures, ● between the concentrations of LPS or 
IMQ for the same time of culture, and * between 24 and 72 h cultures. Control (non-activated cells), 
LPS1 (1µg/ml), LPS0.01 (0.01µg/ml), IMQ5 (5µg/ml), and IMQ1 (1µg/ml). The levels of probability 
were indicated as follows (*p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001, and similarly for 
other symbols). 
 
Summary: 
1. The activation of B cells through TLR4 or TLR7 ligands (LPS and IMQ           
respectively) increased the percentage of CD80, CD86 positive B cells, 
counteracted the decrease of the percentage of CD40 positive B cells, and did 
not influence the percentage of MHC II positive B cells. 
2. The activation of B cells through TLR4 or TLR7 ligands strongly increased 
the expression of MHC II, CD86 and CD40, with minor effect on CD80 
expression. 
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3. All these changes showed that TLR4 and TLR7-mediated B cell activation 
modulate the potential of B cells to present antigens and activate CD4+ T 
cells. 
4. We did not observe any substantial differences in the percentage of positive B 
cells for all of investigated markers upon activation by LPS or IMQ (with one 
exception for CD80 positive B cells in LPS1 activated cultures compared to 
both concentrations of IMQ). Similar difference has been observed for the 
expression of CD86. 
3.1.2. Thymocyte subsets distribution in co-cultures of splenic B cells and 
thymocytes 
To follow the role of B cells in the development of nTregs we investigated the 
sequential developmental steps and the effect of activation of B cells on normal 
distribution of thymic subsets. Additionally, we examined the effect of thymocytes : B 
cells ratio on the efficiency of nTreg generation in vitro. These experiments were 
performed to examine if B cells in direct contact with thymocytes are able to shift the 
development to CD4+ thymocytes containing also the precursors of nTregs. Thus, we 
have examined this in different experimental conditions: using booth non-activated 
and LPS- or IMQ-activated B cells co-cultured with intact (non-pre-activated 
thymocytes (Ctrl).   
It has been documented that nTreg cells represent a minor population of thymocytes. 
It consists of about 4% of the SP CD4+ thymocytes (Fontenot et al., 2005), and a few 
Foxp3+ thymocytes are also detected in the double positive (DP) CD4+CD8+ subset 
(Lee and Hsieh, 2009). Accordingly, the normal distribution of thymocyte subsets 
(DN, DP, SP CD4+, and SP CD8+) was studied in thymocytes culture alone (Ctrl) 
and compared to the distribution of these subsets in the 24 h and 72 h co-cultures of 
thymocytes with splenic B cells to evaluate the effect of B cell activation on this 
process.  
We excluded the high concentration of IMQ (5µg/ml) as the outcome of IMQ-
mediated activation was similar for both concentrations used (Fig. 3.1 and 3.2).  
The distribution of the main thymocyte subsets in the co-cultures of thymocytes with 
splenic B is presented in Figure 3.3. We have observed that the co-culture 
(thymocytes : B cells ratio 10:1) significantly increased the percentage of DN 
thymocytes and decreased the percentage of DP thymocytes compared to thymocytes 
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culture alone (Ctrl) (Fig. 3.3 A and B 24 h). These results suggest the possible block 
in the development of DN thymocytes to DP stage, while maintaining the control 
level of SP CD4+ thymocytes. The effect of splenic B cells interaction with 
thymocytes resulted in the significant decrease of SP CD8+ thymocytes compared to 
the control group (Fig. 3.3 C and D 24 h). This effect did not depend on the activation 
of B cells. 
When the co-culture was extended to 72 h, thymocyte distribution was similar to 24 h 
co-culture (Fig. 3.3 A, B, and D 72 h) except SP CD4+ thymocytes. The percentage 
of these thymocytes decreased in the presence of non-activated and LPS1-activated B 
cells and reached the control level when B cells were activated by the low dose of 
LPS and IMQ1 (Fig. 3.3 C 72 h). The distribution of the thymocyte subsets showed 
the similar pattern in thymocytes : B cells ratio 1:1 (Fig. 3.4). 
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Figure 3.3:— Distribution of thymocyte subsets.  
The experiments have been performed in triplicates. Thymocyte subsets distribution was analyzed after 
24 and 72 h of in vitro culture in thymocytes culture alone (Ctrl, control non-pre-activated thymocytes) 
(white bars) and in co-culture with splenic B cells (black bars, thymocytes : B cells ratio 10:1). DN (A), 
DP (B), SP CD4+ (C), and SP CD8+ (D). The significance values were indicated as ▲ between Ctrl 
and co-cultures. Ctrl (non-pre-activated thymocytes), non-activated (non-activated co-culture), LPS1 
(1µg/ml), LPS0.01 (0.01µg/ml), and IMQ1 (1µg/ml). The levels of probability were indicated as 
follows (▲p < 0.05; ▲▲p < 0.01; ▲▲▲p < 0.001; and ▲▲▲▲p < 0.0001).  
  
 - 67 - 
A                                24h                                                       72h 
  
B 
   
C 
   
D 
  
Figure 3.4:— Distribution of thymocyte subsets. 
The experiments have been performed in triplicates. Thymocyte subsets distribution was analyzed after 
24 and 72 h of in vitro culture in thymocytes culture alone (Ctrl, control non-pre-activated thymocytes) 
(white bars) and in co-culture with splenic B cells (black bars, thymocytes : B cells ratio 1:1). DN (A), 
DP (B), SP CD4+ (C), and SP CD8+ (D). The significance values were indicated as ▲ between Ctrl 
and co-cultures, and ● between non-activated and activated co-cultures. Ctrl (non-pre-activated 
thymocytes), non-activated (non-activated co-culture), LPS1 (1µg/ml), LPS0.01 (0.01µg/ml), and 
IMQ1 (1µg/ml). The levels of probability were indicated as follows (▲p < 0.05; ▲▲p < 0.01; ▲▲▲p < 
0.001; and ▲▲▲▲p < 0.0001, and similarly for ●).  
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Summary: 
1. The presence of B cells in co-culture with thymocytes resulted in increased 
percentage of DN thymocytes and decreased percentage of DP thymocytes 
independently of B cell activation and duration of culture.  
2. B cells did not change the distribution of SP CD4+ thymocytes in all 
conditions of 24 h culture, whereas influenced the percentage of these 
thymocytes in 72 h culture. 
3. The presence of B cells in co-culture with thymocytes reduced the percentage 
of the SP CD8+ thymocytes in all conditions of culture independently on the 
duration of culture. 
3.1.3. Viability of thymocytes in different culture conditions 
  The viability of DP, DN, SP CD4+, and SP CD8+ thymocytes in thymocytes 
culture alone (Ctrl) and co-cultures of thymocytes and B cells has been investigated in 
order to check if the changes of thymocyte subsets distribution resulted from 
differential survival of thymocytes or differences in their development. The results of 
our studies showed that the contact of thymocytes with B cells increased the viability 
of thymocytes or at least maintained the control level of viability (Fig. 3.5). The 
increase of the viability depended on the ratio of thymocytes to B cells, and was 
increased at 1:1 ratio. The viability of all thymocytes increased upon activation of B 
cells by the higher concentration of LPS, and this increase reached significance level 
in the ratio 1:1. In this setting, LPS1 and IMQ1 induced the increase of the viability 
compared to non-activated co-culture (DN), while only LPS1 increased the viability 
of SP CD8+ in co-culture compared to non-activated co-culture (Fig. 3.5 A and D).  
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Figure 3.5:— Viability of thymocyte subsets. 
 DN (A), DP (B), SP CD4+ (C), and SP CD8+ (D)  subsets in thymocytes culture alone as Ctrl (white 
bars) or in co-culture with splenic B cells (black bars) (thymocytes : B cells ratio 10:1 left), and (1:1 
right) .  
The experiments have been performed in triplicates. The cells were analyzed after 72 h of in vitro 
culture. The significance values were indicated as ▲ between Ctrl and co-cultures, and ● between non-
activated and activated co-cultures. Ctrl (non-activated thymocytes), non-activated (non-activated co-
culture), LPS1 (1µg/ml), LPS0.01 (0.01µg/ml), and IMQ1 (1µg/ml). The levels of probability were 
indicated as follows (▲p < 0.05; ▲▲p < 0.01; ▲▲▲p < 0.001; and ▲▲▲▲p < 0.0001, and similarly for 
●). 
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 Summary: 
1. The viability of all thymocytes (DN, DP and SP) co-cultured with B cells did 
not change substantially when B cells were not activated independently on 
thymocytes : B cells ratio (except cultures of 1:1 ratio, DP and SP CD4+).  
2. The viability of DN thymocytes increased upon B cell activation and reached 
the highest percentage in LPS1- and IMQ1-conditioned media and depended 
on thymocytes : B cells ratio. 
3. B cells to thymocytes ratio 1:1 was more efficient in increasing the viability of 
thymocytes. We suggest that the presence of B cells is crucial for thymocytes 
survival.  
4. These results demonstrated that the distribution of thymocyte subsets in co-
culture with B cells did not depend on differential survival potential of 
particular thymocyte subsets, but rather on the process of thymocyte 
development. 
3.1.4. Generation of Foxp3+ thymus-derived Tregs in co-cultures of thymocytes 
and splenic B cells  
The percentage of mature nTregs in thymocytes co-cultured with splenic B 
cells has been studied. The percentage of terminally differentiated nTregs 
characterized by the expression of Foxp3 in SP CD4+ was analyzed (Fig. 3.6). The 
percentage of nTregs increased significantly in the presence of activated B cells in 
both 24 and 72 h co-cultures in both thymocytes : B cells ratios (Fig. 3.6). The 
increase of the percentage of nTregs was independent of the type of B cell activator 
and was similar for LPS and IMQ.  
Short-term cultures (24 h) at 10:1 ratio resulted in the increase of nTregs only in the 
presence of activated B cells compared to incubation of thymocytes alone in culture 
medium (Fig. 3.6 A). When co-culture of thymocytes with splenic B cells extended to 
72 h, the percentage of nTregs in all conditions of culture decreased compared to 24 
h, however, the percentage of nTregs was still higher than in the culture of 
thymocytes alone both in the presence of activated and non-activated B cells (Fig. 3.6 
B). 
After changing of thymocytes : B cells ratio to 1:1 we observed statistically 
significant increase in the percentage of nTregs in the presence of non-activated and 
activated B cells independently on the type of TLR ligand used (Fig. 3.6 C and D). In 
72 h cultures, the percentages of nTregs in all culture conditions were significantly 
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lower than in 24 h cultures. These results indicate that the availability of splenic B 
cells in co-cultures depends on their number, and thymocytes to B cells ratio might 
provide proportional signals important for thymic nTreg precursors to differentiate 
mature Foxp3 expressing nTregs. In addition, B cell activation provided a strong 
signal inducing nTreg generation. Accordingly, the results also suggested that role of 
the degree of B cells activation in relation to LPS concentration; however, the effect 
was not statistically significant.  
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Figure 3.6:— Generation of CD4+Foxp3+ (nTreg) cells.  
The experiments have been performed in triplicates. The cells were analyzed after 24 h (A and C) and 
72 h (B and D) of in vitro culture in thymocytes culture alone as Ctrl. (white bars) or in co-culture with 
splenic B cells (black bars) (thymocytes : B cells ratio 10:1 A and B), and  (ratio 1:1 C and D). The 
significance values were indicated as ▲ between Ctrl and co-cultures, and ● between non-activated and 
activated co-cultures. Ctrl (non-activated thymocytes), non-activated (non-activated co-culture), LPS1 
(1µg/ml), LPS0.01 (0.01µg/ml), and IMQ1 (1µg/ml). The levels of probability were indicated as 
follows (▲p < 0.05; ▲▲p < 0.01; ▲▲▲p < 0.001; and ▲▲▲▲p < 0.0001, and similarly for ●). 
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The prolongation of culture to 5 days demonstrated that additional signals should be 
provided to sustain the percentage of nTregs, however the pattern of changes in the 
co-cultures of thymocytes and activated B cells was maintained as in 24 h of culture 
(Fig. 3.7).  
 
 
 
        CD4 
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Figure 3.7:— Generation of CD4+Foxp3+ (nTreg) cells in long-term co-cultures with B cells.  
The experiments have been performed in triplicates. The cells were analyzed after 5 days of in vitro 
culture in thymocytes culture alone as Ctrl (white bar) or in co-culture with splenic B cells (black bars) 
(thymocytes : B cells ratio 10:1). The significance values were indicated as ▲ between Ctrl and co-
cultures, and ● between non-activated and activated co-cultures. Ctrl (non-activated thymocytes), non-
activated (non-activated co-culture), LPS1 (1µg/ml), LPS0.01 (0.01µg/ml), and IMQ1 (1µg/ml). The 
levels of probability were indicated as follows (▲p < 0.05; ▲▲p < 0.01; ▲▲▲p < 0.001; and ▲▲▲▲p 
< 0.0001, and similarly for ●). 
 
Summary: 
1. Splenic B cells increased the percentage of nTregs in co-cultures with 
thymocytes. 
2. The increase of nTregs percentage depends on B cell activation, culture 
duration and thymocytes to B cells ratio.  
3. The increase of the percentage of nTregs did not depend on the TLR ligands 
used in the study (LPS and IMQ).  
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3.1.5. Sequential steps of thymus-derived Treg development in co-cultures of 
thymocytes and splenic B cells  
Sequential steps of nTreg development were analyzed as measured by the 
expression of CD25 and Foxp3 on SP CD4+ thymocytes. CD4+CD25+Foxp3– cells 
were considered immature nTregs and CD4+CD25+Foxp3+ cells fully mature nTregs. 
The percentage of immature CD4+CD25+ nTregs was increased in co-cultures with B 
cells, and the increase depended on the presence of B cells and their number rather 
than on their activation status (Fig. 3.8 A). The percentage of CD25 positive cells in 
SP CD4+ thymocytes in co-culture (independently on thymocytes to B cells ratio) 
increased in both non-activated and activated cultures compared to Ctrl. In addition, 
the increase was significant in all culture conditions, but was more significant in 
cultures of ratio 1:1 than in the other ratio (Fig. 3.8 A).   
The percentage of mature CD4+CD25+Foxp3+ nTregs was strictly dose- and B cell 
ratio-dependent (Fig. 3.8 B). The percentage of nTregs in all culture conditions 
increased compared to Ctrl. Additionally, this percentage increased when B cells : 
thymocytes ratio increased from 1:10 to 1:1. When B cells were activated by LPS1 or 
IMQ1, the percentage was highly increased compared to non-activated and activated 
by LPS0.01 cultures (Fig. 3.8 B). Collectively, the analysis of sequential steps of 
nTregs development revealed that B cells have an indispensable role in the generation 
of nTregs and the percentage of these cells increased when B cells were activated 
through TLR4 and TLR7 ligands compared to non-activated cultures.  
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Figure 3.8:— Steps of nTreg maturation in co-cultures with B cells. 
The percentage of CD25 positive thymocytes in SP CD4+ subset (A), and Foxp3 positive thymocytes in 
CD4+CD25+ subset (B).  
The experiments have been performed in triplicates. The cells were analyzed after 72 h of in vitro 
culture in thymocytes culture alone as Ctrl (white bars) or in co-culture with isolated splenic B cells 
(black bars) (thymocytes : B cells ratio 10:1 left), and (ratio 1:1 right).  
The significance values were indicated as ▲ between Ctrl and co-cultures, and ● between non-activated 
and activated co-cultures. Ctrl (non-activated thymocytes), non-activated (non-activated co-culture), 
LPS1 (1µg/ml), LPS0.01 (0.01µg/ml), and IMQ1 (1µg/ml). The levels of probability were indicated as 
follows (▲p < 0.05; ▲▲p < 0.01; ▲▲▲p < 0.001; and ▲▲▲▲p < 0.0001, and similarly for ●). 
   
Summary: 
1. The co-culture of thymocytes and B cells resulted in the expression of CD25 
on the SP CD4+ thymocytes and induction of Foxp3. 
2. The expression of CD25 did not depend on the B cell activation but rather on 
thymocytes to B cells ratio. 
3. The expression of Foxp3 strongly depends on the B cell activation, but not on 
the type of B cell activator. 
3.1.6. Expression of Foxp3 in thymus-derived Tregs in different culture 
conditions 
Considering the role of Foxp3 in the suppressive activity of nTregs we 
evaluated its expression in different culture conditions (Fig. 3.9). Our results revealed 
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clearly that the presence of B cells in culture of thymocytes (independently on 
thymocytes to B cells ratio) increased the expression of Foxp3 by developing nTregs. 
Additionally, our results revealed that the ratio of activated-splenic B cells has a 
crucial role in the expression of Foxp3 in nTregs (Fig. 3.9 A and B). The type of 
activator (LPS or IMQ) was of less importance.  
A         B 
  
Figure 3.9:— The expression of Foxp3 molecule in nTreg cells in co-cultures with B cells. 
The experiments have been performed in triplicates. The cells were analyzed after 72 h of in vitro 
culture in different conditions of thymocytes culture alone as Ctrl (white bars), or in co-culture with 
isolated splenic B cells (black bars) (thymocytes : B cells ratio 10:1 A), and (ratio 1:1 B).  
The significance values were indicated as ▲ between Ctrl and co-cultures, and ● between non-activated 
and activated co-cultures. Ctrl (non-activated thymocytes), non-activated (non-activated co-culture), 
LPS1 (1µg/ml), LPS0.01 (0.01µg/ml), and IMQ1 (1µg/ml). The levels of probability were indicated as 
follows (▲p < 0.05; ▲▲p < 0.01; ▲▲▲p < 0.001; and ▲▲▲▲p < 0.0001, and similarly for ●). 
 
Summary: 
1. The contact of thymocytes and splenic B cells resulted in the increase of 
the expression of Foxp3 independently on the ratio of thymocytes to B 
cells; however, the effect was strengthened by a higher number of B cells. 
2. B cell activation increased the B cell-dependent up-regulation of Foxp3 in 
nTregs. 
3. The type of activator was of minor importance in the increase of the 
expression of Foxp3. 
3.1.7. Expression of co-stimulatory molecules and MHC II on splenic B cells in 
co-culture with thymocytes 
To examine the role of contact between thymocytes and B cells on the 
antigen-presenting potential of B cells we studied the expression of co-stimulatory 
molecules and MHC II. The percentage of B cells positive for CD80 and CD86 
increased in co-cultures with thymocytes after B cell activation; however, this 
percentage was lower than in the culture of splenic B cells alone (Fig. 3.10 A and B). 
We suggest that this may result from the presence of thymus-derived B cells 
 - 78 - 
consuming LPS and IMQ either because of the expression of respective TLRs or 
changes of the kinetics of CD80 and CD86 expression caused by the contact between 
B cells and thymocytes. The percentage of CD40-positive B cells was lower in co-
culture with thymocytes, however, in 72 h co-culture activation of B cells or presence 
of thymocytes showed the tendency to maintain the percentage of CD40-positive B 
cells diminished during the culture longer than 24 h (Fig. 3.10 C). The percentage of 
MHCII-positive B cells in co-cultures with thymocytes was decreased compared the 
culture of B cells alone reaching the control level in 72 h co-culture (Fig. 3.10 D).  
In general, changes in the percentage of B cells expressing MHC II and co-
stimulatory molecules were not caused by the contact with thymocytes, and the 
observed differences may reflect the activity of thymus-derived B cells taking part in 
the consumption of activators (TLR ligands). Indeed, our results revealed that the 
mere presence of thymocytes did not change the percentage of CD80 and CD86-
positive B cells (except CD80/72 h). The percentage is increased by B cell activation, 
but at lower level than in cultures of B cells alone. We may suggest that thymic B 
cells compete with splenic B cells for TLR ligands, and the effects observed in B cell 
cultures alone are weakened in co-cultures with total thymic cells. 
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Figure 3.10:— The percentage of co-stimulatory molecules and MHC II expressing B cells in co-
cultures with thymocytes.  
CD80 (A), CD86 (B), CD40 (C), and MHC II (D). White bars represent B cells cultured alone; black 
bars represent B cells co-cultured with thymocytes in thymocytes : B cells ratio 10:1. The experiments 
have been performed in triplicates. The cells were analyzed after 24 and 72 h of in vitro culture. The 
significance values were indicated as▲ between Control (non-activated) and activated B cells in 24 or 
72 h cultures, ● between the concentrations of LPS or IMQ for the same time of culture, and * between 
24 and 72 h cultures. Control (non-activated cells), LPS1 (1µg/ml), LPS0.01 (0.01µg/ml), IMQ5 
(5µg/ml), and IMQ1 (1µg/ml). The levels of probability were indicated as follows (*p < 0.05; **p < 
0.01; ***p < 0.001; and ****p < 0.0001, and similarly for other symbols). 
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We have observed that the expression of CD80 on B cells after 24 and 72 h co-
cultures increased compared to splenocytes cultured alone and the increase was 
statistically significant upon activation by LPS1 (Fig. 3.11 A). The mere presence of 
thymocytes in co-cultures resulted in up-regulation of CD86 in both durations of 
culture. After activation, the expression of this molecule decreased in 24 h co-cultures 
compared to splenocytes cultured alone (Fig. 3.11 B). The expression of CD40 and 
MHC II was also decreased in co-culture with thymocytes (Fig. 3.11 C and D). The 
results of this part of the study revealed that the presence of thymocytes in activated 
co-culture induced the up-regulation of CD80 and down-regulation of CD86, CD40, 
and MHC II and these changes were time and type of activator-dependent.  
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Figure 3.11:— The expression of co-stimulatory molecules and MHC II on B cells co-cultured with 
thymocytes. 
CD80 (A); CD86 (B); CD40 (C) and MHC II (D). White bars represent B cells cultured alone; black 
bars represent B cells co-cultured with thymocytes in thymocytes : B cells ratio 10:1. The experiments 
have been performed in triplicates. The cells were analyzed after 24 and 72 h of in vitro culture. The 
significance values were indicated as▲ between Control (non-activated) and activated B cells in 24 or 
72 h cultures, ● between the concentrations of LPS or IMQ for the same time of culture, and * between 
24 and 72 h cultures. Control (non-activated cells), LPS1 (1µg/ml), LPS0.01 (0.01µg/ml), IMQ5 
(5µg/ml), and IMQ1 (1µg/ml). The levels of probability were indicated as follows (*p < 0.05; **p < 
0.01; ***p < 0.001; and ****p < 0.0001, and similarly for other symbols). 
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Summary: 
1. The mere presence of B cells did not affect the percentage of CD80 and CD86 
positive splenic B cells, and these percentages were increased upon activation 
by LPS1 and IMQ1 even if the percentage was lower than in splenocytes 
culture alone under the same culture conditions. 
2. The level of CD80 in co-culture was higher than of the same condition for 
splenocytes culture alone. 
3.1.8. Role of co-stimulatory molecules and MHC II blocking on thymus-derived 
Treg generation in co-culture of thymocytes and splenic B cells 
To determine the role of co-stimulatory molecules in nTreg generation 
blockade of these molecules on B cells was performed. This part of the study 
consisted of the following steps:1/ multiple molecule blockade using anti-CD80 + 
anti-CD86 + anti-CD40 + anti-MHC II simultaneously; 2/ single molecule blockade 
using anti-CD80, anti-CD86, anti-CD40, and anti-MHC II separately; 3/ paired 
blockade using anti-MHC II and anti-co-stimulatory molecule, namely: anti-CD80 + 
anti-MHC II, anti-CD86 + anti-MHC II, and anti-CD40 + anti-MHC II. The results of 
blocking experiments are presented on Fig. 3.12. 
We showed that the blockade of all analyzed molecules resulted in more than 5-fold 
decrease in percentage of nTregs compared to activated sample (Fig. 3.12 a). The 
effect of both B7 molecules in the generation of nTregs was evenly matched between 
each other by decreasing the percentage of nTregs generation 2-fold compared with 
activated samples but the effect of CD86 was stronger than the effect of CD80 and for 
both strategies of blockade (anti-B7 or anti-B7 + anti-MHC II) (Fig. 3.12 b, c, f, and 
g). CD40 seemed to be less important as it decreased the percentage of nTregs 1-fold 
only (Fig. 3-12 d). However, this inhibitory effect was more significant in 
combination with MHC II (Fig. 3.12 h).  
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Figure 3.12:— Effect of MHC II and co-stimulatory molecules blockade on nTreg generation. 
The cultures were activated by LPS1 (1µg/ml). The cells were analyzed after 24 h of in vitro co-culture 
with thymocytes ( thymocytes : B cells ratio 1:1). The significance values were indicated as▲ between 
Control (non-activated cells) and activated culture, and ● between activated culture and blockade 
cultures. The small letters beside activator indicated as following: CD80+CD86+CD40+MHC II 
molecules have been blocked (a), CD80 molecule has been blocked (b), CD86 molecule has been 
blocked (c), CD40 molecule has been blocked (d), MHC II molecule has been blocked (e), 
CD80+MHC II molecules have been blocked (f), CD86+MHC II molecules have been blocked (g), and 
CD40+MHC II molecules have been blocked (h). The levels of probability were indicated as follows 
(●p < 0.05; ●●p < 0.01; ●●●p < 0.001; and ●●●●p < 0.0001, and similarly for ▲). 
  
Summary: 
1. All molecules (MHC II, CD80, CD86, and CD40) play a role in the generation 
of nTregs.  
2. Blocking of pairs of molecules (MHC II and one co-stimulatory) and blocking 
all of them resulted in the strong inhibition of nTreg generation. We suggest 
that CD86 highly influence nTreg generation in our experimental model, and 
the decrease of nTregs percentage is as strong as in the case of blockade of all 
the studied molecules. 
 
 
 
CD4 
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3.1.9. Biological activity of thymus-derived Tregs generated in co-cultures with 
splenic B cells 
We have investigated the biological activity of in vitro generated 
CD4+Foxp3+ nTregs using the functional assay based on the suppressive activity of 
nTregs on the proliferation of responder activated CD4+ T cells. Anti-CD3 (0.5 
µg/ml) and anti-CD28 (0.05 µg/ml) were used for CD4+ T cells activation thereby to 
induce proliferation of these cells. (Fig. 3.13). 
 
Figure 3.13:— Biological activity of in vitro generated nTregs. 
 Non-activated responder T cells (Control), activated responder T cells (Without nTregs), and co-
culture of activated responder T cells & nTregs isolates from co-culture with B cells activated with 
LPS (With nTregs).   
The experiments have been performed in triplicates. The cells were analyzed after 72 h of in vitro 
culture. The significance values were indicated as▲ between (without nTregs) and (control), and ● 
between (without nTregs) and (with nTregs). The percentage of inhibition was 34.28% in (with nTregs 
culture), according to equation described in materials and methods section. The levels of probability 
were indicated as follows (▲p < 0.05; ▲▲p < 0.01; ▲▲▲p < 0.001; and ▲▲▲▲p < 0.0001, and 
similarly for ●). 
 
The results demonstrated that nTregs in the co-culture of thymocytes with LPS-
activated splenic B cells showed the suppressive activity against activated target 
CD4+ T cells. 
Summary: 
1. Thymus-derived Tregs generated in the co-culture of thymocytes and activated 
B cells exhibited the potential to inhibit the proliferation of activated 
responder T cells. 
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3.1.10. Thymocyte subsets distribution in co-cultures of anti-CD3 pre-activated 
thymocytes and splenic B cells  
We have demonstrated that in the population of nTreg precursors exposed to 
weak signal from TCR and strong signal from co-stimulatory molecule receptors the 
percentage of Foxp3+ thymocytes in CD4+ subset was increased in 24 h co-cultures. 
The percentage of nTregs was still higher in 72 h co-cultures; however, the absolute 
value was lower than in 24 h co-cultures (Fig. 3.6). To demonstrate the effect of 
strong signal from TCR on nTreg generation in co-cultures anti-CD3 pre-activated 
thymocytes with B cells activated longer than 24 h have been performed. In this 
modified conditions of co-culture the previous experimental variant was performed. 
The 72 h of culture was chosen to demonstrate the effect of the strong signal.  
The effect of anti-CD3 pre-activation of thymocytes on the distribution of thymocyte 
subsets in the co-cultures with LPS- or IMQ-activated B cells has been investigated. 
Thymocyte pre-activation by CD3 monoclonal antibodies and further co-culture with 
B cells resulted in strong increase of the percentage of DN and decrease of the 
percentage of DP thymocytes, which can suggest a developmental block at the DN to 
DP stage or DP differentiation into SP thymocyte subsets. At the same time the 
increase of the percentage of SP CD4+ was observed in the presence of B cells 
activated by the higher concentration of LPS. The increase of the percentage of SP 
CD8+ thymocytes was observed in all co-culture conditions. 
 LPS1-activated B cells decreased the percentage of DN thymocytes, whereas 
activation by LPS0.01 and IMQ1 decreased this subset compared to the co-culture 
containing non-activated B cells (Fig. 3.14 A). LPS1-activated B cells decreased the 
percentage of DP thymocytes, and activation by LPS0.01 and IMQ1 increased this 
subset compared to the co-culture containing non-activated B cells (Fig. 3.14 B). 
Interestingly, LPS1-activated B cells significantly increased the percentage of SP 
CD4+ thymocytes whereas the activation by low dose of LPS decreased the 
percentage of this subset compared to the co-culture containing non-activated B cells 
(Fig. 3.14 C). Both low doses of activators significantly increased the percentage of 
SP CD8+ thymocytes whereas higher dose of LPS did not affect the percentage of this 
subset compared to the co-culture containing non-activated B cells (Fig. 3.14 D).  
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Lack of anti-CD3 pre-activation step, as we demonstrated in previous section (3.1.2), 
resulted in decreased percentage of both SP CD4+ and SP CD8+ thymocytes. 
            A                                                              B 
                      
             C                                                               D 
 
 Figure 3.14:— Effect of anti-CD3 thymocyte pre-activation on the distribution of the main thymocyte 
subsets. 
A/ DN thymocytes; B/ DP thymocytes; C/ SP CD4+ thymocytes; D/ SP CD8+ thymocytes. Ctrl, a-CD3 
(white bars): thymocytes cultured alone without B cells; black bars: a-CD3 pre-activated thymocytes 
co-cultured with non-activated B cells and activated by LPS or IMQ (thymocytes : B cells ratio 1:1).  
The experiments have been performed in triplicates. The cells were analyzed after 72 h of in vitro 
cultures. The significance values were indicated as ▲ between ctrl and co-cultures, and ● between 
non-activated and activated B cells. anti-CD3(Ctrl) (pre-activated thymocytes), a-CD3 (pre-activated 
co-culture), a-CD3&LPS1 (pre-activated+LPS1µg/ml), a-CD3&LPS0.01(pre-activated+LPS 0.01µg/ 
ml), and a-CD3& IMQ1(pre-activated+IMQ 1µg/ml). The levels of probability were indicated as 
follows (▲p < 0.05; ▲▲p < 0.01; ▲▲▲p < 0.001; and ▲▲▲▲p < 0.0001, and similarly for ●).  
 Summary: 
1. Anti-CD3 pre-activation of thymocytes followed by co-culture with B cells led 
to the increase of SP thymocyte subsets, mainly SP CD8+. The activation of B 
cells in this process was of minor importance for SP CD8+ differentiation. 
2. The increase of the percentage of SP CD4+ thymocytes was statistically 
significant only after B cell activation by high dose LPS. 
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3. The presence of B cells resulted in the strong increase of DN and decrease of 
DP thymocytes. 
3.1.11. Generation of Foxp3+ thymus-derived Tregs in co-cultures of anti-CD3 
pre-activated thymocytes and splenic B cells  
The content of nTregs was evaluated in 72 h co-cultures of CD3-pre-activated 
thymocytes and B cells (Fig. 3.15). Pre-activation of thymocytes by CD3 monoclonal 
antibodies and further co-culture with B cells resulted in the strong increase of 
nTregs. We found that the presence of splenic B cells was important when thymocytes 
received strong signal via TCR by anti-CD3 activation, as it caused the increased 
generation of nTregs. In these conditions (anti-CD3 activation) the activation of B 
cells was of minor importance. 
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Figure 3.15:— Percentage of CD4+Foxp3+ (nTregs) in co-cultures of anti-CD3 pre-activated 
thymocytes and B cells. 
Ctrl, anti-CD3 (white bar): thymocytes cultured alone without B cells; black bars: anti-CD3 pre-
activated thymocytes co-cultured with non-activated B cells and activated by LPS or IMQ (thymocytes 
: B cells ratio 1:1). The experiments have been performed in triplicates. The cells were analyzed after 
72 h of in vitro cultures. The significance values were indicated as ▲ between ctrl and co-cultures, and 
● between non-activated and activated B cells. anti-CD3(Ctrl) (pre-activated thymocytes), anti-CD3 
(pre-activated co-culture), a-CD3&LPS1 (pre-activated+LPS1µg/ml), a-CD3&LPS0.01(pre-
activated+LPS 0.01µg/ml), and a-CD3& IMQ1(pre-activated+IMQ 1µg/ml). The levels of probability 
were indicated as follows (▲p < 0.05; ▲▲p < 0.01; ▲▲▲p < 0.001; and ▲▲▲▲p < 0.0001, and 
similarly for ●).  
LPS1-activated B cells increased the percentage of nTregs, whereas B cells activated 
by either LPS0.01 or IMQ1 significantly decreased the percentage of nTregs 
compared to either pre-activated thymocytes or non-activated B cells (Fig. 3.15). This 
result strongly suggested the role of B cells in the generation of nTregs because the 
presence of non-activated B cells increased the number of nTregs. After B cell 
activation, when B cells received strong signal from TLR4 ligand (LPS1 activation), 
the percentage of generated nTreg was maintained while when B cells received weak 
signal from either TLR4 or TLR7 (activation by LPS0.01 or IMQ1) the percentage of 
generated nTreg significantly decreased compared to pre-activated thymocytes (Ctrl). 
We cannot give any scientific interpretation to the observed decrease in number of 
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nTreg after pre-activation and activation by low doses of both activators. To fully 
understand these observations further studies are required. 
Summary: 
1. Pre-activation of thymocytes by CD3 monoclonal antibodies followed by co-
culture with B cells resulted in increase of nTregs. The activation of B cells 
was of minor importance after administration of high dose LPS. 
2. Low concentration of LPS and IMQ counteracted the effect of anti-CD3 pre-
activation.  
3.1.12. The role of co-stimulatory molecules and MHC II blocking on thymus-
derived Treg generation in co-culture of anti-CD3 pre-activated thymocytes and 
splenic B cells 
To determine the role of co-stimulatory molecules and MHC II expressed on 
splenic B cells in nTreg generation blocking antibodies were used. In this step the co-
cultures were incubated for 24 h only as because the after this time the highest 
percentage of generated nTregs was observed.  
Our results have revealed that blockade of all studied molecules decreased the 
percentage of nTregs (Fig. 3.16). The strongest inhibition of generation of nTreg was 
observed in the after CD86 and CD80 blockade; however, the effects of CD40 
blockade were also evident. Simultaneous blockade of all molecules led to absolute 
abolition of nTreg generation. These results are in accordance with previously 
presented data (Fig. 3.12) showing the results of molecules blockade in thymocytes 
co-cultures with activated B cells. 
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Figure 3.16:— The effect of co-stimulatory molecules and MHC II blockade on nTreg generation.  
The cells were analyzed after 24 h of in vitro co-culture with thymocytes (thymocytes : B cells ratio 
1:1). The significance values were indicated as ● between blockade samples and a-CD3&LPS1 sample. 
The small letters beside activator indicated as following: CD80+CD86+CD40+MHC II molecules have 
been blocked (a), CD80 molecule has been blocked (b), CD86 molecule has been blocked (c), CD40 
molecule has been blocked (d), MHC II molecule has been blocked (e), CD80+MHC II molecules have 
been blocked (f), CD86+MHC II molecules have been blocked (g), and CD40+MHC II molecules have 
been blocked (h). The levels of probability were indicated as follows  (●p < 0.05; ●●p < 0.01; ●●●p < 
0.001; and ●●●●p < 0.0001). 
 
Summary: 
1. MHC II, CD80, CD86, and CD40 play an important role in the generation of 
nTregs. 
2. The results of our studies showed that CD80/CD86 molecules are of major 
importance for nTreg development.  
Discussion 
We hypothesized that B cells can be involved in the generation of natural 
regulatory T cells. Our hypothesis was built on the following facts: firstly, the normal 
development of nTreg in the thymus requires interaction with thymic antigen-
presenting cells such as dendritic cells and thymic epithelial cells (van Santen et al., 
2004; Pennington et al., 2006). These cells present antigens to developing nTreg for 
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their selection and maturation (Jenkinson et al., 1994; Volkmann et al., 1997). 
Secondly, it was found that a minor percentage of B cells reside in the thymus, and 
the precise function and origin of these cells are still controversial (Kleindienst et al., 
2000; Hashimoto et al., 2002; Ceredig et al., 2007). In addition, nTreg cells have a 
crucial role in maintaining the immune system homeostasis and control the 
pathological and physiological responses. The percentage of these cells is limited, and 
they comprise about 4% of SP CD4+ cells (Fontenot et al., 2005). We introduced a 
model of co-culture of thymocytes with splenic B cells to investigate if B cells, which 
can serve as antigen-presenting cells for peptide antigens (Vascotto et al., 2007; 
Taneja et al., 2007; Roux and Niedergang, 2012), have the potential to induce the 
generation of nTregs in in vitro.  
Recently it was documented that many phenotypically different B cells can be 
involved in the induction of Tregs in peripheral lymphoid organs (Chen et al., 2009; 
Zheng et al., 2010). In addition, it was shown that B cells are available in the thymus 
and are involved in negative selection of autoreactive CD4+ thymocytes (Frommer 
and Waisman, 2010). Our model was created to examine if peripheral B cells can 
influence the generation of nTregs from thymic precursor cells. Based on the results 
of Bieńkowska et al. (Bieńkowska et al., 2014) on the role of different sources of 
activatory signals necessary to the generation of thymic Tregs, we have used splenic 
B cells as antigen-presenting cells providing necessary signals for nTreg maturation.   
It is known that B cells can serve as antigen-presenting cells and we have confirmed it 
in our data by showing the expression of co-stimulatory and MHC II molecules on 
splenic B cells activated through TLR4 and TLR7 (bacterial and viral infection-
mimicking agents which represent the common pathogens for our body). In addition, 
these molecules are important for further interaction with conventional T cells during 
their activation (Chambers, 2001; Salomon and Bluestone, 2001). Accumulated 
evidence indicates that CD28/B7 interactions not only regulate T cell activation but 
are also required for the development (Tang et al., 2003; Liang et al., 2005) and 
homeostasis of CD4+CD25+ Tregs (Salomon et al., 2000).The expression of CD80, 
CD86, and CD40 have been investigated because these molecules are crucial in the 
signal transduction to T cells playing a role of co-stimulatory molecules for T cells 
activation and differentiation into effector populations (van Kooten and Banchereau, 
1997; Tang et al., 2003; Liang et al., 2005; Lu et al., 2015). Splenic B cells constitute 
a large population of lymphocytes with full capacity to internalize, process and 
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present antigen to T cells. For instance, in vitro studies have found that the ability of 
activated B cells to activate naïve CD4+ T cells is almost as high as that of DCs 
(Cassell and Schwartz, 1994). On the other hand, in vitro responses of B cells to LPS 
or IMQ are different, and the outcome of such stimulation is strongly dose-dependent 
(Coutinho et al., 1974; Dziarski, 1982; Suvas et al., 2002; Sauder, 2003). In this 
regard, LPS can modulate antigen internalization and regulate different molecules in 
dose dependent manner (Xu et al., 2008). Our results revealed that a significant 
population of splenic B cells expresses co-stimulatory molecules and MHC II and 
their expression were up-regulated after 24 h upon activation by T-independent 
stimuli. This result is consistent with the results of other researchers who have 
observed up-regulation of co-stimulatory molecules upon activation (Suvas et al., 
2002; Xu et al., 2008). In our culture conditions B cells constitutively express low 
level of CD80. This result differs from the results of others which revealed that B 
cells did not normally express CD80 but this molecule could be inducible (Lenschow 
et al., 1996). 
We examined the effect of the presence of B cells on the distribution of the main 
thymocyte subsets and concluded that B cells increase SP CD4+ content as was 
observed in co-cultures of thymocytes and JAWS II cells acting as antigen-presenting 
cells (Bieńkowska, 2014). These experiments were performed to see if the contact of 
thymocytes with B cells (non-activated or activated through TLR4 or TLR7) results in 
the differentiation toward SP CD4+ thymocytes which can further mature to nTregs. 
The increase of DN thymocytes and the decrease of DP thymocytes (in LPS and IMQ-
activated and anti-CD3-pre-activated co-cultures) may result from the developmental 
block at the DN/DP stage, differentiation of DP to SP or differential sensitivity of 
thymocyte subsets to apoptosis manifested by changes in percentage values of 
thymocyte subsets. Moreover, the activation of B cells, especially by LPS1, in the co-
culture with thymocytes increased viability of SP CD4+, but not SP CD8+ 
thymocytes, which additionally favored SP CD4+ differentiation. Bieńkowska et al. 
have shown that providing two activatory signals using anti-CD3 and JAWS II cells 
(delivering co-stimulatory signal) shifted the differentiation of DP thymocytes into SP 
CD4+ thymocytes (Bieńkowska et al., 2014). In other study 7-fold increase in 
thymocyte numbers was observed in mice treated with superagonist (SA) anti-CD28 
antibodies. The treatment induced proliferation of mature thymocytes, but did not 
accelerate differentiation of DP thymocytes (Legrand et al., 2006). 
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To examine the role of B cells in nTreg generation we followed a standardized 
protocol facilitating the assessment of sequential steps of nTreg generation based on 
the distribution of thymocyte subsets and maturation stage of nTregs as measured by 
CD25 and Foxp3 expression in SP CD4+ thymocytes. To follow the sequential steps 
of nTreg development, CD25 expression in SP CD4+ cells and subsequently Foxp3 
expression in CD4+CD25+ cells have been investigated. The results revealed that the 
presence of B cells resulted in the induction of CD25 on SP CD4+ thymocytes and 
substantial maturation of nTregs (Foxp3 induction) (Fig. 3.8).  
The main goal of our studies was to investigate the role of B cells in the generation of 
nTregs in in vitro. We hypothesize that B cells isolated from spleens can deliver both 
signals important to developing nTreg and in consequence induce their maturation. It 
was found that Tregs are induced by TCR signals below the threshold limit for 
negative selection and above the required affinities for conventional TCRs. nTreg 
selection seems to be directed by high affinity interaction of TCR with either self 
(Jordan et al., 2001; Kawahata et al., 2002) or foreign antigens (Pacholczyk et al., 
2007). Thus, to prove our hypothesis, co-cultures of isolated splenic B cells with 
thymocytes containing nTreg precursors have been performed. According to the two-
step model for nTreg differentiation (Burchill et al., 2008; Lio and Hsieh, 2008) 
developing nTregs (nTreg precursor) require co-stimulation signals from TCR/CD28 
interactions with their ligands on B cells to induce the expression of CD25. It was 
documented that there was a significant reduction in the number of Tregs in thymus of 
CD28
−/−
 mice and mice treated with anti-B7 antibodies (Tang et al., 2003; Lohr et al., 
2004; Tai et al., 2005). Furthermore, markedly reduced numbers of peripheral 
CD4+CD25+ Tregs compartment in B7-1 and B7-2-deficient non-obese diabetic 
(NOD) mice was observed (Salomon et al., 2000). These observations support the 
importance of interaction between B7 and CD28 molecules in the nTreg generation. 
In our model the first step of nTreg development was accomplished by mere presence 
of B cells in co-cultures, that provided a weak signal to TCR. To strengthen this 
signal anti-CD3 activation step was further performed. Our results have shown that B 
cells can provide both signals required for generation of nTregs even without 
activation. The percentage of nTregs after anti-CD3 pre-activation increased 2-fold 
compared to previous co-culture activated by LPS1 (Fig. 3.6 and 3.15). This result is 
consistent with other findings showing that pre-activation of thymocytes by anti-CD3 
before their culture with JAWS II cells was necessary for extensive generation of 
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nTregs (Bieńkowska et al., 2014). nTreg precursors need additional signal (for 
example from IL-2 or other cytokines or molecules) to induce the expression of 
Foxp3. In the aforementioned experiment non-activated B cells were not able to 
provide this signal to nTreg precursors. On the other hand, our result revealed that 
mere presence of B cells in co-culture can induce the expression of Foxp3 compared 
to thymocytes cultured alone (Ctrl) (Fig. 3.9). Additionally, B cell activation was 
crucial to induce Foxp3 expression in CD4+CD25+ thymocytes. Induction of Foxp3 
requires an agonist self-peptide, and the frequency of nTreg cells that develop is 
directly proportional to the strength of the signal (Relland et al., 2009). Thus, 
activation of B cells used in the present study through TLR4 and TLR7 ligands 
increased the expression of co-stimulatory molecules, and in consequence increased 
the potential of B cells to generate nTregs. In addition, thymocytes : B cells ratio was 
pivotal for nTreg generation by B cells (Fig. 3.8). We have shown that the activation 
of B cells and/or increased number of B cells in co-cultures can be sufficient to induce 
Foxp3 expression and maturation of developing nTregs. These results clearly 
confirmed the role of B cells in the generation of nTregs by up-regulation of Foxp3 
expression in developing nTregs (Fig. 3.9). Thus, activated B cells have the potential 
to generate nTregs by providing co-stimulatory signals to developing nTregs. These 
results are concordant with data published previously (Bieńkowska et al., 2014). 
 We showed that increased percentage of nTregs did not depend on TLR ligands used 
in the study (LPS and IMQ). These results suggest that the optimal conditions for 
nTreg generation in vitro depend on two factors: the presence of B cells (the 
percentage of nTregs increased with the increase of relative B cells number), and the 
B cells activation state (the percentage of nTregs increased in LPS and IMQ activated 
co-cultures). On the other hand, it was reported that many cells and molecules can 
induce the generation of Tregs, for instance the interaction of T cells with tolerogenic 
dendritic cells, anti-inflammatory cytokines, glucocorticoids, vitamins, or other 
suppressive molecules produced by pathogens (Bettelli et al., 2006). In our studies 
thymic nTreg was generated in the presence of splenic B cells activated by LPS and 
IMQ. 
To elucidate if splenic B cells have the ability to induce the proliferation of generated 
nTreg, the proliferation of nTregs in various culture conditions has been investigated. 
We did not record any proliferation of nTregs in all control conditions (thymocytes 
cultured alone), what indicates that nTregs in control did not receive any signal 
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neither from thymic B cells nor from activators through TLRs and thereby they were 
unable to proliferate. This result is consistent with the results of Bieńkowska et al. 
who found that nTregs could not proliferate in control and in cultures activated with 
anti-CD3 only, whereas the highest proliferation was recorded when nTregs were 
provided with two signals (using anti-CD3 antibodies and JAWS II cell line as a 
source of co-stimulatory signal)  (Bieńkowska et al., 2014). However, the 
proliferation of nTregs in co-culture of splenic B cells with thymocytes strongly 
depended on the ratio of B cells. nTregs revealed low level of proliferation in all 
culture conditions (thymocytes : B cells ratio 10:1). When the ratio of splenic B cells 
in co-culture with thymocytes has changed from 10:1 to 1:1, a small level of 
proliferation of nTregs was observed (data not shown because the number of events in 
the examined sample was not adequate for proper proliferation analysis, thereby we 
cannot show this result as a histogram). 
To characterize the potential of B cells to generate nTregs in vitro, the expression of 
co-stimulatory molecules as well as MHC II in co-culture with thymocytes have been 
studied. We have shown that the expression of CD80 molecule on splenic B cells 
increased in co-culture with thymocytes compared to Ctrl, whereas the results of 
CD86, CD40, and MHC II molecules expression on splenic B cells were the opposite 
(Fig. 3.10 and 3.11). This observation should be interpreted in relation to the 
following facts. The affinity of CD86 on B cells to CD28 on T cells is 2-3-fold higher 
than that of CD80 (Collins et al., 2002), while the affinity of CTLA-4 to CD80 and 
CD86 is about 100-fold higher (depending on the ligand) than that of CD28 (Sansom 
et al., 2003). Moreover, CD86 is expressed constitutively and is rapidly up-regulated 
following T cell interaction with APCs, while CD80 is up-regulated at later stages of 
the immune response (Lenschow et al., 1996). Although CD28 is the preferred 
receptor for CD86, CTLA-4 binds mostly to CD80 (Pentcheva-Hoang et al., 2004; 
Evans et al., 2005). CD28 is constitutively expressed on naïve T cells, while CTLA-4 
is not expressed constitutively and its expression is up-regulated upon T cell 
activation. For these reasons, we suggest that the down-regulation of some molecules 
and up-regulation of others on splenic B cells in co-culture with thymocytes compared 
to Ctrl may be due to interaction with their ligand/s on T cells able to transmit signal/s 
from B cell to T cell.  
It has been suggested that nTregs require at least two signals for their generation, but 
the involvement of different molecules and cytokines in this process is still 
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controversial (Tang et al., 2003; Hsieh et al., 2006; Liston and Rudensky, 2007; Bayer 
et al., 2007; Moore et al., 2010; Bieńkowska et al., 2014; Lu et al., 2015).Thus, we 
have investigated the role of different molecules expressed by B cells on the 
generation of nTregs using molecule-blockade strategy by antagonist antibody. We 
have shown that the effect of B7 (CD80 and CD86) and MHC II molecules were more 
pronounced than that of CD40 molecule, and MHC II molecule has a pivotal role in 
the generation of nTregs (Fig. 3.12). We concluded that B cells can play a pivotal role 
in the generation of nTregs and can provide both signals needed for nTregs 
maturation. Additionally, B cells provide these signals through MHC II and co-
stimulatory molecules, and the signal provided by CD80/CD86 is more efficient than 
signal provided by CD40. This result is consistent with previously published data 
(Salomon et al., 2000; Tang et al., 2003; Bour-Jordan et al., 2004; Tang et al., 2004; 
Lohr et al., 2004;  Spence and Green, 2008; Bieńkowska et al., 2014). 
We investigated the biological activity of nTregs generated from LPS1-activated co-
cultures. CD4+ T cells were activated by anti-CD3/CD28 to induce proliferation. 
nTreg cells isolated from co-cultures effectively and significantly decreased activated 
CD4+ T cells. These results indicate that generated nTregs can exert suppressive 
activity against CD4+ T cells in in vitro conditions (Fig. 3.13). In vitro generated 
nTregs in can be used for the treatment of autoimmune diseases and prevention of 
transplant rejection (Chai et al., 2005; Shevach, 2006; Roncarolo and Battaglia, 2007; 
Haribhai et al., 2009; 2011; Lim et al., 2010; Qian et al., 2011; Nishikawa and 
Sakaguchi, 2014). However, results of other studies indicated that Tregs generated 
using different strategies in in vitro cultures were not always characterized by 
suppressive function and in many cases failed to suppress target cells (Prado et al., 
2011). Additionally, other results showed that iTregs generated by activation with 
anti-CD3/CD28 antibodies differ from those generated by the physiological-like 
activation with antigen/APC (Zhao et al., 2014). Thus, different strategies of nTreg 
generation may give different results.    
The pre-activation by anti-CD3 monoclonal antibody increased percentage of nTregs 
in thymocytes cultured alone compared to non-pre-activated thymocytes (1.10% and 
0.26%, respectively). Additionally, the mere presence of splenic B cells in 72 h of co-
culture with pre-activated thymocytes induced the increase of the percentage of 
nTregs indicating to the role of B cells in the generation of nTreg, while activation of 
B cells with pre-activation was of minor importance (Fig. 3.15). Collectively these 
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results revealed that the pre-activation with anti-CD3 (providing strong signal via 
TCR) could increase the percentage of nTregs when developing cells also receive 
second signal from B cells.  
In this study, we introduce a novel method for nTregs generation by interaction with 
splenic B cells as APC.  
 
3.2. Thymic B cells in the development of thymus-derived Tregs: preliminary 
studies 
The results from the first section of the current study clearly confirmed the 
role of splenic B cells in the generation of nTregs in in vitro model. Additionally, 
these results revealed that B cells highly up-regulated MHC II as well as co-
stimulatory molecules upon activation with TLR4 and TLR7 ligands resulting in 
increased number of nTregs generated in the presence of activated splenic B cells. It 
is considered that a very small number of B cells reside in the thymus and their 
contribution to nTreg generation was neglected in the experiments presented in the 
first section. To answer the question if thymic B cells play a role in the generation of 
nTregs we performed the following examinations: 
1/ The percentage of nTregs in thymic cells cultured in the presence of LPS and IMQ. 
2/ The percentage of thymic B cells in control medium and in LPS- and IMQ-
conditioned medium. 
3/ The expression of MHC II and co-stimulatory molecules on thymic B cells cultured 
in LPS- and IMQ-conditioned medium. 
3.2.1. Role of thymic B cells in the generation of thymus-derived Tregs and 
Foxp3 expression in vitro 
There is a small population of B cells in thymus (between 0.10  0.50%) 
(Frommer and Waisman, 2010; Perera et al., 2013) and their function and origin are 
still controversial. There are two suggested origins of thymic B cells. The first group 
has suggested that thymic B cells develop in the thymus from thymic B-cell 
progenitors and differ from recirculating peripheral B cells (Hashimoto et al., 2002; 
Perera et al., 2013; Perera and Huang, 2015). Second group argued that thymus 
contains mature B cells and the migration of peripheral B cells to the thymus might 
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increase several fold in certain pathological situations such as thymic lymphoma 
(Michie and Rouse, 1991) and some murine models of autoimmune diseases (Hart 
and Zan-Bar, 1991). Activation of thymic B cells with LPS and IMQ constitutes did 
not change the percentage of nTregs in the 24 h culture and increased in 72 h culture 
compared to non-activated controls (Fig. 3.17). Activation by LPS and IMQ did not 
change the percentage of nTreg regardless of duration of the culture. It is clearly 
depicted that the percentage of nTregs in 72 h culture is maintained at the same level 
as after 24 h demonstrating that B cell activation results from their increased survival. 
 
Figure 3.17:— The percentage of CD4+Foxp3+ thymocytes in the culture of thymus-derived cells. 
The experiments have been performed in triplicates. The ells were analyzed after 24h (white bars) and 
72h (black bars) of in vitro culture. The significance values were indicated as▲ between Control (non-
activated) and activated cells in 24 or 72 h cultures, and * between 24 and 72 h cultures. Control (non-
activated cells), LPS1 (1µg/ml), LPS0.01 (0.01µg/ml), and IMQ1 (1µg/ml). The levels of probability 
were indicated as follows (*p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001, and similarly for 
▲). 
 
The expression of Foxp3 was not changed upon activation by LPS and IMQ, with the 
exception of IMQ-supplemented medium, which caused the statistically significant up-
regulation Foxp3 (Fig. 3.18). 
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Figure 3.18:— The expression of Foxp3 molecule in nTreg cells in different conditions of thymus-
derived cells. 
The experiments have been performed in triplicates. The cells were analyzed after 72h of in vitro culture. 
The significance values were indicated as ▲ between Control (non-activated cells) and activated cells. 
Control (non-activated thymocytes), LPS1 (1µg/ml), LPS0.01 (0.01µg/ml), and IMQ1 (1µg/ml). The 
levels of probability were indicated as follows (▲p < 0.05; ▲▲p < 0.01; ▲▲▲p < 0.001; and ▲▲▲▲p 
< 0.0001). 
 
Summary: 
1. The percentage of nTregs of control cultures decreased in time-dependent 
manner. 
2. The percentage of nTregs in 24 h culture of thymocytes of LPS and IMQ-
conditioned medium was not changed. 
3. LPS and IMQ-mediated activation counteracted the decrease of nTregs in 72 h 
cultures maintaining the level observed in 24 h control culture by supporting 
their survival.  
4. LPS and IMQ-supplemented medium did not substantially influence the 
expression of Foxp3 in nTregs.  
3.2.2. B cells content in the culture of thymus-derived Tregs of LPS and IMQ-
supplemented medium 
 In physiological conditions B cells represent approximately 0.50% of the 
thymic cellularity. Although their absolute number may exceed that of thymic 
dendritic cells, their role as antigen-presenting cells for central tolerance induction is 
not well understood (Yamano et al., 2015b). It was estimated that apart from the 
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release of about 1×106 T cells, each day the thymus exports around 3×104 of B cells 
(Akashi et al., 2000), which is a good evidence suggesting that part of the thymic B 
cells differentiate within the thymus. The percentage of B cells was strongly increased 
of our experimental conditions (LPS and IMQ-supplemented medium). Increased 
percentage of B cells was observed in 72 h cultures, which suggests that both 
activators induced proliferation. This suggestion is additionally confirmed by the fact 
that the increase of B cells depended on the concentration of the activator (namely of 
LPS) (Fig. 3.19).  
 
Figure 3.19:— The percentage of B cells in the culture of thymus-derived cells. 
The experiments have been performed in triplicates. The cells were analyzed after 24 h (white bars)  
and 72 h (black bars) of in vitro culture. 
The significance values were indicated as ▲ between Control (non-activated) and activated cells in 24 
or 72 h cultures, and * between 24 and 72 h cultures. Control (non-activated thymocytes), LPS1 
(1µg/ml), LPS0.01 (0.01µg/ml), and IMQ1 (1µg/ml). The levels of probability were indicated as 
follows (▲p < 0.05; ▲▲p < 0.01; ▲▲▲p < 0.001; and ▲▲▲▲p < 0.0001, and similarly for *). 
 
Summary: 
1. LPS and IMQ supplementation resulted in increased percentage of B cells 
suggesting activator-induced proliferation of thymic derived B cells.  
3.2.3. Expression of co-stimulatory molecules and MHC II on thymic B cells  
We have investigated the expression of MHC II and co-stimulatory molecules 
on thymic B cells upon activation by LPS and IMQ. Unlike splenic B cells, the 
percentage of thymic B cells expressing CD80 and CD86 increased in LPS1- and 
IMQ1-activated 72 h cultures compared to 24 h (Fig. 3.20 A and B). Considering a 
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small number of thymic B cells, the concentrations of activators, LPS and IMQ, were 
high enough to saturate TLR4 and TLR7 maintaining the increased expression of 
molecules throughout the culture. The lower concentration of LPS was not effective 
in increasing the percentage of CD80 and CD86-positive B cells. LPS1 stimulation 
increased the percentage of CD86+ B cells in a time-dependent manner, whereas 
IMQ1 stimulation increased the percentage of CD86+ B cells only in 72 h cultures 
(Fig. 3.20 B). The percentage of CD40+ B cells was slightly increased upon 
activation with LPS1 and significantly decreased upon activation with LPS0.01 and 
IMQ1 in 24 h cultures (Fig. 3.20 C). LPS at higher concentration induced the increase 
of the percentage of MHC II+ thymic B cells in 72 h cultures while decreasing the 
percentage of MHC II+ B cells upon activation by the lower concentration of LPS and 
IMQ1 (Fig. 3.20 D). 
A                                                           B 
   
C                                                             D 
 
Figure 3.20:— The effect of LPS and IMQ on the percentage of thymic B cells positive for MHC II and 
co-stimulatory molecules. CD80 (A), CD86 (B), CD40 (C), and MHC II (D) in vitro. 
The experiments have been performed in triplicates. The cells were analyzed after 24 (white bars) and 
72 (black bars) hours of in vitro culture. The significance values were indicated as▲ between Control 
(non-activated) and activated cells in 24 or 72 h cultures, and * between 24 and 72 h cultures.  Control 
(non-activated cells), LPS1 (1µg/ml), LPS0.01 (0.01µg/ml), and IMQ1 (1µg/ml). The levels of 
probability were indicated as follows (*p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001, and 
similarly for ▲). 
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CD80, CD86, CD40, and MHC II expression on thymic B cells is presented on Fig. 
3.21. Unlike the percentage of thymic B cells positive for these molecules, the 
expression of MHC II and co-stimulatory molecules in B cells increased after 24 h 
cultures compared to 72 h cultures (except the expression of MHC II in IMQ1-
activated culture/72 h). LPS1 and IMQ1 stimulation significantly increased the 
expression of CD80 in both culture durations as compared to control (Fig. 3.21 A), 
however, the up-regulations expression was inversely dependent on the time of 
culture. Similar correlations have been observed for the expression of CD86, CD40 
and MHC II upon activation by LPS1 and IMQ1 (with the exception of MHC II for 
IMQ1). The expression of CD86 increased upon activation by LPS1 and IMQ1 
compared to control, and was also inversely dependent on time (Fig. 3.21 B). LPS1 
and IMQ1 stimulation induced up-regulation of CD40 and MHC II in a similar 
inversely time-dependent manner (Fig. 3.21 C and D).The diminished expression of 
the majority of molecules in 72 h cultures with the simultaneous increase of the 
percentage of positive B cells for these molecules point on the induction of 
investigated markers on negative B cells upon activation followed by the retarded up-
regulation of their expression.  
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A                                                                B 
 
   
C                                                               D 
  
Figure 3.21:— The expression of co-stimulatory molecules. CD80 (A); CD86 (B); CD40 (C); and 
MHC II (D) on LPS and IMQ activated thymic B cells. 
The experiments have been performed in triplicates. The cells were analyzed after 24 (white bars) and 
72 (black bars) hours of in vitro culture. The significance values were indicated as▲ between Control 
(non-activated) and activated cells in 24 or 72 h cultures, and * between 24 and 72 h cultures.  Control 
(non-activated cells), LPS1 (1µg/ml), LPS0.01 (0.01µg/ml), and IMQ1 (1µg/ml). The levels of 
probability were indicated as follows (*p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001, and 
similarly for ▲). 
Summary: 
1. LPS and IMQ activation resulted in the up-regulation of CD80, CD86, CD40, 
and MHC II on thymic B cells. 
2. The up-regulation of CD80, CD86, CD40, and MHC II correlated with the 
increase of the percentage of B cells-positive for these molecules upon 
activation by LPS1.   
Discussion 
In this section, we have focused on the possible role of thymus-derived B cells 
in the generation of nTregs.  
Thymus contains a small population of B cells that colocalize with dendritic cells and 
medullary thymic epithelial cells in the thymic medulla (Perera et al., 2013; Walters et 
al., 2014). The development and functional significance of these cells are 
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controversial. It was documented that the majority of thymic B cells are B1-cells 
(Inaba et al., 1990; Sugihara et al., 2000; Ceredig, 2002). B cells are considered 
inefficient in presenting antigens via nonspecific uptake, however, capture and 
internalization of cognate antigens with subsequent presentation is very efficient 
(Pierce et al., 1988; Lanzavecchia, 1990). Thus, for a particular antigen B cells 
specific to that antigen could be the most efficient antigen-presenting cells on a per 
cell basis. 
In our experimental settings thymic B cells did not influence the generation of nTregs, 
but rather maintain their viability when activated by both studied activators (LPS or 
IMQ). They revealed the typical characteristics of antigen-presenting cells when 
activated by LPS and IMQ, which up-regulated MHC II and co-stimulatory molecules 
expression. This result differed from the result published by others who found that 
thymic B cells did not respond to stimulation by LPS or IL-4 and expressed low level 
of MHC II upon activation (Inaba et al., 1990). This discrepancy may result from the 
differences in experimental model. 
It was documented that thymic B cells have a pivotal role in the generation of nTregs 
(Walters et al., 2014). In addition, thymic B cells are involved in negative selection of 
auto-reactive CD4+ thymocytes whereas nTregs can spare from this process thereby 
the percentage of nTregs was increased (Frommer and Waisman, 2010). In addition to 
the role of thymic B cells in the generation and/or selection of nTregs (Frommer and 
Waisman, 2010; Perera et al., 2013; Walters et al., 2014; Lu et al., 2015), we have 
shown that activated thymic B cells maintained the viability of thymic nTregs as 
confirmed by increased percentage of nTregs compared to non-activated 72 h culture 
(Fig. 3.17). Our results documented the role of thymic B cells in supporting the 
viability of thymic Tregs. Consistent with this result, it was documented that the 
generation of nTregs in thymus is accomplished in two steps. In the first step, thymic 
B cells promote the generation of thymic pre-nTreg thymocytes from CD4 single 
positive thymocytes. In the second step, thymic B cells directly promote the 
proliferation of thymic Treg cells both in vivo and in vitro in MHC II-dependent 
manner with a minimal-role for the co-stimulatory molecules CD40 and CD80/86 (Lu 
et al., 2015). 
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Our results revealed that unlike splenic B cells, the percentage of thymic B cells 
expressing both MHC II and co-stimulatory molecules (but not the expression of these 
molecules) up-regulated in 24 h cultures and continued to increase during incubation 
upon activation by T-independent stimuli (LPS and IMQ) compared to control, 
indicating that thymic and splenic B cells derive from different origins. In addition, 
thymic B cells maturated after 24 h of activation and served as mature cells during 
further incubation (Fig. 3.20). Thymic B cells may proliferate upon activation via 
TLR4 and TLR7 because the percentage of B cells in thymus significantly increased in 
activated cultures compared to non-activated cultures/72 h (Fig. 3.19). This result was 
consistent with previously published data (Inaba et al., 1990). 
 
3.3. Effect of dexamethasone on the generation of thymus-derived Tregs in the 
co-culture of thymocytes and splenic B cells  
Glucocorticoids exert multiple effects on immune cells, such as induction of 
apoptosis and up- or down-regulation of genes expression (Elenkov, 2004) including 
Foxp3 of Tregs (Prado et al., 2011). Glucocorticoids are known for their 
immunosuppressive effects, and are widely used as potent immunosuppressive agents 
in different immune diseases and experimental settings (Madden and Felten, 1995; 
Tarcic et al., 1998; Yoshimura et al., 2001).  
Dexamethasone (Dex) is a synthetic glucocorticoid widely used as a potent suppressor 
of inflammatory response. It has been documented that tolerogenic dendritic cells 
contribute to the induction of Tregs. Treatment of human monocyte-derived DC or 
mouse bone marrow-derived DC with Dex conditioned these cells for tolerogenic 
phenotype and activity to induce T regulatory cells (Maldonado and von Andrian, 
2010). Ligand binding to the glucocorticoid receptor regulates DC activation through 
nuclear glucocorticoid response elements that negatively regulate promoters for genes 
involved in canonical NF-κB pathway, inflammatory cytokines, chemokines, their 
receptors and antigen presentation molecules (Leung and Bloom, 2003). In addition to 
repressing DC maturation, Dex also induces expression of multiple anti-inflammatory 
genes and chemoattractants, including IL-10, GITRL, IDO, CCL2 (MCP-1), CCL8 
(MCP-2), CCR2, CCL9 (MIP-1c) and CCLl2 (MIP-2) (Roca et al., 2007; Grohmann 
et al., 2007). This impairs the ability of DCs to migrate and provokes them to aquire a 
tolerogenic phenotype capable of directing naïve T cells to express CD25 and Foxp3. 
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On the other hand, the inhibitory effect of glucocorticoids on NF-κB pathway likely 
plays a key role in the conversion of DCs to the tolerogenic phenotype. Also, 
inhibition of NF-κB or IKKβ by small molecule antagonists generates tolerogenic 
DCs able to stimulate Foxp3+CD25+ Tregs and alleviate symptoms of EAE, heart 
allograft rejection, and intestinal bowel disease (Buckland et al., 2006; Iruretagoyena 
et al., 2006; Zhang et al., 2008; Buckland and Lombardi, 2009; Cong et al., 2009). 
Moreover, tolerogenic DCs are able to promote differentiation and proliferation of 
regulatory T cells (Huang et al.,2010),  and can be generated ex vivo from peripheral 
blood monocytes modulated by different approaches, including conditioning with 
pharmacological agents such as Dex and rapamycin (Matsue et al., 2002; Unger et al., 
2009).  
The aim of the studies presented in this section was to investigate whether 
dexamethasone can induce a tolerogenic potential of B cells similarly to its effect on 
dendritic cells and facilitate the generation of nTregs from thymic precursors. In order 
to complete this part of the study the following tasks have been performed: 
1/ Examination of the role of Dex on the expression of MHC II and co-stimulatory 
molecules (CD80, CD86, and CD40) on splenic B cells upon activation by LPS and 
IMQ. 
2/ Investigation of the role of Dex on the distribution of the main thymocyte subsets. 
3/ Determination of the effect of Dex on the generation of thymus-derived Treg cells 
in co-culture with splenic B cells. 
4/ Analysis of the effect of Dex on the expression of MHC II and co-stimulatory 
molecules on splenic B cells in co-culture with thymocytes. 
5/ Evaluation of Dex-induced B cells apoptosis in different culture conditions.   
3.3.1. The effect of dexamethasone on the expression of MHC II and co-
stimulatory molecules on splenic B cells 
As it was shown previously, the percentage of splenic B cells expressing 
CD80, CD86, CD40, and MHC II was increased upon activation by LPS and IMQ. 
The percentage of B cells expressing MHC II and co-stimulatory molecules was 
decreased significantly in the presence of Dex (Fig. 3.22, 3.23, 3.24, and 3.25).  
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The percentage of CD80+ splenic B cells activated by LPS and IMQ in the presence 
of Dex is presented on Figure 3.22.  
A                                                             B 
    
C                                                         D 
   
Figure 3.22:— The effect of dexamethasone on the percentage of CD80+ splenic B cells activated with 
LPS and IMQ. LPS1 (1µg/ml) (A), LPS0.01 (0.01µg/ml) (B), IMQ5 (5µg/ml) (C), and IMQ1 (1µg/ml) 
(D). 
The experiments have been performed in triplicates. The cells were analyzed after 24 (white bars) and 
72 (black bars) hours of in vitro culture. The significance values were indicated as ● between activated 
and activated+Dex cultures, and  ⃰ between 24 and 72 h cultures. Dex was used in the following 
concentrations; 10
-8
 (10
-8 
M), 10
-9
 (10
-9 
M), 10
-10
 (10
-10 
M), 10
-11
 (10
-11 
M), and 10
-12
 (10
-12 
M). The 
levels of probability were indicated as follows (*p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 
0.0001, and similarly for ●).    
 
Dex decreased the percentages of CD80+ B cells both in LPS and IMQ activated 
cultures. The decrease was inversely proportional to the level of activation of B cells 
(by signals delivered from a particular TLR) characterized by the percentage of 
CD80+ splenic B cells in activated cultures without Dex. Most potent decrease of the 
percentage of CD80+ B cells was obtained in the presence of the highest 
concentration of Dex (10
-8
M). This concentration induced 5-fold and 1-fold decrease 
of CD80+ B cells in LPS1-activated cultures after 24 and 72 h of incubation, 
respectively. On the other hand, the same concentration decreased this percentage 6-
fold and 7-fold in LPS0.01-activated cultures for 24 and 72 h, respectively (Fig. 3.22 
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A and B). The same effect was observed in IMQ-activated cultures. The decrease was 
time dependent for all doses of activators (Fig. 3.22 C and D). 
Dex decreased the percentages of CD86+ B cells both in LPS and IMQ activated 
cultures. In LPS-activated cultures, the decrease was inversely proportional to the 
level of activation of B cells and proportional to the concentration of Dex, while the 
decrease of the percentage was similar in both IMQ-activated cultures. The decrease 
was time dependent for all doses of activators (Fig. 3.23 A, B, C and D).  
A                                                          B 
   
C                                                          D 
   
Figure 3.23:— The effect of dexamethasone on the percentage of CD86+ splenic B cells activated with 
LPS and IMQ. LPS1 (1µg/ml) (A), LPS0.01 (0.01µg/ml) (B), IMQ5 (5µg/ml) (C), and IMQ1 (1µg/ml) 
(D). 
The experiments have been performed in triplicates. The cells were analyzed after 24 (white bars) and 
72 (black bars) hours of in vitro culture. The significance values were indicated as ● between activated 
and activated+Dex cultures, and  ⃰ between 24 and 72 h cultures. Dex was used in the following 
concentrations; 10
-8
 (10
-8 
M), 10
-9
 (10
-9 
M), 10
-10
 (10
-10 
M), 10
-11
 (10
-11 
M), and 10
-12
 (10
-12 
M). The 
levels of probability were indicated as follows (*p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 
0.0001, and similarly for ●). 
 
Dex decreased the percentages of CD40+ B cells both in LPS and IMQ activated 
cultures. The decrease was inversely proportional to the level of activation of B cells. 
This dependence was more pronounced in LPS-activated B cell cultures (Fig. 3.24 A 
and B). Low concentration of LPS decreased the sensitivity to Dex in 72 h culture 
resulting in an increase of CD86+ B cells compared to 24 h culture and diminution of 
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the difference in the percentage of positive B cells compared to appropriate activated 
control culture without Dex. This effect was not observed in cultures activated by 
high concentration of LPS as well as both concentrations of IMQ. The effect of Dex 
was dose- and duration-dependent for LPS-activated cultures, however, it was neither 
dose of activator nor duration-dependent for IMQ-activated cultures (Fig. 3.24 A, B, 
C and D). 
A                                                          B 
                        
      C                                                          D 
   
Figure 3.24:— The effect of dexamethasone on the percentage of CD40+ splenic B cells activated with 
LPS and IMQ. LPS1 (1µg/ml) (A), LPS0.01 (0.01µg/ml) (B), IMQ5 (5µg/ml) (C), and IMQ1 (1µg/ml) 
(D). 
The experiments have been performed in triplicates. The cells were analyzed after 24 (white bars) and 
72 (black bars) hours of in vitro culture. The significance values were indicated as ● between activated 
and activated+Dex cultures, and  ⃰ between 24 and 72 h cultures. Dex was used in the following 
concentrations; 10
-8
 (10
-8 
M), 10
-9
 (10
-9 
M), 10
-10
 (10
-10 
M), 10
-11
 (10
-11 
M), and 10
-12
 (10
-12 
M). The 
levels of probability were indicated as follows (*p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 
0.0001, and similarly for ●). 
     
Dex decreased the percentages of MHC II+ B cells both in LPS- and IMQ-activated 
cultures. The suppressive effect of Dex on the percentage of MHC II+ B cells was 
substantially weaker than on co-stimulatory molecules (Fig. 3.25 A, B, C and D). 
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A                                                             B 
   
C                                                          D 
   
Figure 3.25:— The effect of dexamethasone on the percentage of MHC II+ splenic B cells activated 
with LPS and IMQ. LPS1 (1µg/ml) (A), LPS0.01 (0.01µg/ml) (B), IMQ5 (5µg/ml) (C), and IMQ1 
(1µg/ml) (D). 
The experiments have been performed in triplicates. The cells were analyzed after 24 (white bars) and 
72 (black bars) hours of in vitro culture. The significance values were indicated as ● between activated 
and activated+Dex cultures, and  ⃰ between 24 and 72 h cultures. Dex was used in the following 
concentrations; 10
-8
 (10
-8 
M), 10
-9
 (10
-9 
M), 10
-10
 (10
-10 
M), 10
-11
 (10
-11 
M), and 10
-12
 (10
-12 
M). The 
levels of probability were indicated as follows (*p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 
0.0001, and similarly for ●). 
 
The expression of CD80, CD86, CD40 and MHC II molecules have been 
investigated. In contrary to its role as suppressive agent decreasing the percentage of 
CD80 positive B cells, some concentrations of Dex (10
-9
 to 10
-12
 M) up-regulated 
CD80 expression independently from the concentrations of activators (LPS or IMQ), 
especially in 72 h cultures (Fig. 3.26). 10
-8 
M concentration of Dex decreased the 
expression of CD80 molecule in 24 h cultures activated by LPS and IMQ. We suggest 
that the apparent increase of CD80 expression resulted from the difference in the 
expression of this molecule among the population of cultured B cells: the expression 
of CD80 was completely inhibited on B cells expressing low level of this molecule 
(the percentage of B cells positive for CD80 was decreased by Dex), leaving B cells, 
which originally showed higher expression of CD80. 
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A                                                            B 
   
C                                                              D 
  
Figure 3.26:— The effect of dexamethasone on the expression of CD80 molecule on splenic B cells 
activated with LPS and IMQ. LPS1 (1µg/ml) (A), LPS0.01 (0.01µg/ml) (B), IMQ5 (5µg/ml) (C), and 
IMQ1 (1µg/ml) (D). 
The experiments have been performed in triplicates. The cells were analyzed after 24 (white bars) and 
72 (black bars) hours of in vitro culture. The significance values were indicated as ● between activated 
and activated+Dex cultures, and  ⃰ between 24 and 72 h cultures. Dex was used in the following 
concentrations; 10
-8
 (10
-8 
M), 10
-9
 (10
-9 
M), 10
-10
 (10
-10 
M), 10
-11
 (10
-11 
M), and 10
-12
 (10
-12 
M). The 
levels of probability were indicated as follows (*p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 
0.0001, and similarly for ●). 
    
The suppressive effect of Dex was mainly observed at the higher concentration of 
LPS in 24 h cultures, and the suppressive effect depended on Dex concentrations. In 
72 h LPS high-activated cultures, two concentrations of Dex (10
-9
 and 10
-10
 M) 
significantly increased the expression of CD86 molecule compared to activated 
sample (Fig. 3.27 A). Low concentration of LPS combined with low concentrations of 
Dex (10
-10
, 10
-11
, and 10
-12 
M) significantly increased the expression of this molecule 
(Fig. 3.27 B). In IMQ-activated cultures, the suppressive effect of Dex was observed 
only in 24 h cultures in the medium containing the highest concentration of Dex (Fig. 
3.27 C and D). 
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A                                                          B 
   
C                                                           D 
  
Figure 3.27:— The effect of dexamethasone on the expression of CD86 molecule on splenic B cells 
activated with LPS and IMQ. LPS1 (1µg/ml) (A), LPS0.01 (0.01µg/ml) (B), IMQ5 (5µg/ml) (C), and 
IMQ1 (1µg/ml) (D). 
The experiments have been performed in triplicates. The cells were analyzed after 24 (white bars) and 
72 (black bars) hours of in vitro culture. The significance values were indicated as ● between activated 
and activated+Dex cultures, and  ⃰ between 24 and 72 h cultures. Dex was used in the following 
concentrations; 10
-8
 (10
-8 
M), 10
-9
 (10
-9 
M), 10
-10
 (10
-10 
M), 10
-11
 (10
-11 
M), and 10
-12
 (10
-12 
M). The 
levels of probability were indicated as follows (*p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 
0.0001, and similarly for ●). 
   
Dex suppressed the expression of CD40 on B cells in the majority of cultures 
independently on the type of activator and duration of culture, and did not affect the 
expression of this molecule in 24 h cultures upon activation by IMQ. 
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A                                                          B 
      
C                                                          D 
  
Figure 3.28:— The effect of dexamethasone on the expression of CD40 molecule on splenic B cells 
activated with LPS and IMQ. LPS1 (1µg/ml) (A), LPS0.01 (0.01µg/ml) (B), IMQ5 (5µg/ml) (C), and 
IMQ1 (1µg/ml) (D). 
The experiments have been performed in triplicates. The cells were analyzed after 24 (white bars) and 
72 (black bars) hours of in vitro culture. The significance values were indicated as ● between activated 
and activated+Dex cultures, and  ⃰ between 24 and 72 h cultures. Dex was used in the following 
concentrations; 10
-8
 (10
-8 
M), 10
-9
 (10
-9 
M), 10
-10
 (10
-10 
M), 10
-11
 (10
-11 
M), and 10
-12
 (10
-12 
M). The 
levels of probability were indicated as follows (*p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 
0.0001, and similarly for ●). 
 
While all concentrations of Dex down-regulated CD40 expression in 72 h cultures 
when added to IMQ-activated cultures, two concentrations of Dex (10
-10
 and 10
-11 
M) 
for IMQ high-activated culture and one concentration of Dex (10
-12
 M) for IMQ low-
activated culture up-regulated this molecule/ 24 h (Fig. 3.28C and D). We suggest that 
the strength of signal delivered to B cells via TLR4/LPS or TLR7/IMQ play a crucial 
role in antagonizing the suppressive effect of Dex in 24 h cultures, however, this 
effect did not sustain for long period of incubation (for 72 h cultures). 
Dex strongly inhibited of MHC II expression independently from the concentrations 
of activators and duration of culture.   
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A                                                         B 
    
C                                                         D 
   
Figure 3.29:— The effect of dexamethasone on the expression of MHC II molecule on splenic B cells 
activated with LPS and IMQ. LPS1 (1µg/ml) (A), LPS0.01 (0.01µg/ml) (B), IMQ5 (5µg/ml) (C), and 
IMQ1 (1µg/ml) (D). 
The experiments have been performed in triplicates. The cells were analyzed after 24 (white bars) and 
72 (black bars) hours of in vitro culture. The significance values were indicated as ● between activated 
and activated+Dex cultures, and  ⃰ between 24 and 72 h cultures. Dex was used in the following 
concentrations; 10
-8
 (10
-8 
M), 10
-9
 (10
-9 
M), 10
-10
 (10
-10 
M), 10
-11
 (10
-11 
M), and 10
-12
 (10
-12 
M). The 
levels of probability were indicated as follows (*p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 
0.0001, and similarly for ●).  
   
Summary: 
1. Dexamethasone suppressed the expression of co-stimulatory molecules that 
was observed as decrease of B cells expressing particular molecules and 
decreased expression level of molecules of interest. CD80 and CD86 
expression was the most affected, and was less potent for CD40. 
2. MHC II expression level was strongly suppressed by dexamethasone 
independently of dexamethasone concentrations and duration of culture 
without substantial effect on the percentage of MHC II+ B cells. 
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3.3.2. The effect of dexamethasone on the distribution of the main thymocyte 
subsets 
The effect of dexamethasone on the distribution of the main thymocyte subsets 
in co-culture with splenic B cells (Thymocytes : B cells ratio 10:1) was examined 
(Fig. 3.30). The distribution of the main thymocyte subsets was not affected by 
dexamethasone.  
                                 A                                                           B                          
 
   
                                     C                                                            D 
  
 
       
  Figure 3.30:— The effect of dexamethasone on the distribution of thymocyte subsets in co-culture 
with splenic B cells (thymocytes : B cells ratio 10:1). DN (A), DP (B), SP CD4+ (C), and SP CD8+ 
(D).   
The experiments have been performed in triplicates. The cells were analyzed after 24 (white bars) and 
72 (black bars) hours of in vitro culture. The significance values were indicated as ● between activated 
and activated+Dex cultures, and  ⃰ between 24 and 72 h cultures. Dex was used in the following 
concentrations; 10
-9
 (10
-9 
M), 10
-11
 (10
-11 
M), and 10
-12
 (10
-12 
M). The levels of probability were 
indicated as follows (*p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001, and similarly for ●).  
 
Summary: 
1. Dexamethasone did not affect the distribution of the main thymocyte subsets 
in co-cultures of thymocytes and B cells activated by LPS and IMQ. 
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3.3.3. Effect of dexamethasone on the generation of thymus-derived Tregs in co-
culture with splenic B cells 
   The presence of Dex in co-cultures (Thymocytes : B cells ratio 10:1) did not 
affect the percentage of nTregs regardless of the duration of culture. The difference in 
the percentage of nTregs between 24 h and 72 h cultures were maintained 
independently of the presence of dexamethasone in culture medium (Fig. 3.31 A). 
A 
    
B 
   
  Figure 3.31:— The effect of dexamethasone on the percentage of CD4+Foxp3+ (nTreg) cells in co-
culture with splenic B cells. (A) (Thy : B ratio=10:1), and (B) (Thy : B ratio=1:1).   
The experiments have been performed in triplicates. The cells were analyzed after 24 (white bars) and 
72 (black bars) hours of in vitro culture. The significance values were indicated as ● between activated 
and activated+Dex cultures, and  ⃰ between 24 and 72 h cultures. Dex was used in the following 
concentrations; 10
-9
 (10
-9 
M), 10
-11
 (10
-11 
M), and 10
-12
 (10
-12 
M). The levels of probability were 
indicated as follows (*p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001, and similarly for ●).  
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Summary: 
1. Dexamethasone did not affect the generation of nTregs in co-cultures of 
thymocytes and activated B cells. 
2. The percentage of nTregs generated in co-cultures of thymocytes and activated 
B cells depended on the Thy : B ratio and B cell activation even in the 
presence of dexamethasone. 
3.3.4. Evaluation of apoptosis of B cells in dexamethasone-conditioned medium 
The percentage of apoptotic splenic B cells has been examined in 24 h cultures 
in the presence of dexamethasone to investigate the effect of different concentrations 
of Dex on the induction apoptosis in B cells and its potential to reduce the number of 
living cells in the cultures. The percentage of apoptotic cells strongly depended on the 
concentration of activators and Dex dose. Dex did not influence the level of apoptosis 
in B cells as compared to control (except from one concentration of Dex (10
-12
M) that 
significantly decreased the percentage of apoptotic cells) (Fig. 3.32 A). The higher 
concentration of LPS and IMQ counteracted the effect of Dex significantly lowering 
the number of apoptotic B cells (Fig. 3.32 B and D). On the other hand, the weak 
signal delivered from low concentration of LPS cannot counteract the suppressive 
effect of Dex, furthermore, the concentration 10
-8
M of Dex was shown to induce 
apoptosis (Fig. 3.32 C).   
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A                                                           B 
   
C                                                              D 
   
Figure 3.32:— Percentage of apoptotic splenic B cells in different conditions of culture.  
The effect of Dex (A), LPS1+Dex (B), LPS0.01+Dex (C), and IMQ1+Dex (D) . The cells were 
analyzed after 24 h of in vitro culture. 
The significance values were indicated as▲ between control and activated culture, and ● between 
activated and activated+Dex cultures. Control (non-activated cells), LPS1 (1µg/ml), LPS0.01 
(0.01µg/ml), and IMQ1 (1µg/ml). Dex was used in the following concentrations; 10
-8
 (10
-8 
M), 10
-9
 (10
-
9 
M), 10
-10
 (10
-10 
M), 10
-11
 (10
-11 
M), and 10
-12
 (10
-12 
M). The levels of probability were indicated as 
follows (▲p < 0.05; ▲▲p < 0.01; ▲▲▲p < 0.001; and ▲▲▲▲p < 0.0001, and similarly for ●). 
 
 
The results show that Dex did not induce apoptosis in B cells with the exception of 
LPS0.01/Dex 10
-8
 M. Activation of B cells diminished the level of apoptosis. Thus, 
down-regulation of co-stimulatory molecules and MHC II did not result from the 
induction of apoptosis of B cells. 
Summary: 
1. Dexamethasone did not increase the level of apoptosis as compared to the 
control. 
2. The activation of B cells by LPS and IMQ lowered the level of apoptosis in 
Dex- supplemented medium. 
3. Low level of apoptosis after activation and Dex treatment depended on the 
concentration of LPS and was not observed for the lower concentration of 
LPS.  
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Discussion 
Some immunosuppressive and anti-inflammatory agents have a potential to 
generate tolerogenic DCs in mice and humans, that in some conditions may lead to 
the induction of regulatory T cells (Adorini et al., 2004). Immature DCs have been 
found to have tolerogenic properties and can induce T cells with suppressive function 
(Jonuleit et al., 2000). It was documented that tolerogenic DCs should exhibit an 
immature phenotype characterized by decreased expression of co-stimulatory B7 
(CD80 and CD86), MHC II, and functional activator (CD40) molecule, which can 
lead to an alternative antigen presentation and co-stimulation (Steinman et al., 2003; 
Ueno et al., 2007; van Kooten et al., 2009). In consequence tolerogenic DCs acquire 
the ability to establish tolerance through the promotion of regulatory T cell responses 
(Pulendran et al., 2010). Furthermore, these tolerogenic DCs can promote the 
differentiation and proliferation of T cells with regulatory functions (Matsue et al., 
2002; Hackstein and Thomson, 2004; Unger et al., 2009; Huang et al., 2010; García-
González et al., 2013). Different studies have shown that in vitro treatment of DCs 
with immunosuppressive agents leads to down-regulation of co-stimulatory molecules 
(CD80, CD86, and CD40), to decreased IL-12 synthesis, and enhanced IL-10 
production, resulting in decreased T-cell activation (Berer et al., 2000; Griffin et al., 
2000; Penna and Adorini, 2000, Piemonti et al., 2000). These properties highlight the 
important functional effects of immunosuppressive agents on DCs and are, at least in 
part, responsible for the induction of DCs with tolerogenic properties (Adorini et al., 
2004).  
Dexamethasone is one of the most investigated immunosuppressive agents (Woltman 
et al., 2006; van Duivenvoorde et al., 2007). It is known as an immunosuppressive 
agent widely used to treat autoimmune diseases and prevent graft rejection (van 
Kooten et al., 2009; Moreau et al., 2012). The effects of Dex on the expression of 
different molecules and induction of apoptosis in different types of lymphocytes have 
been investigated. For instance, Dex causes a reduction of both splenic and lymph 
node B-cell numbers and attenuation of early B-cell progenitor proliferation, 
suppression of IgG and induction of IgE production (Baschant and Tuckermann, 
2010; Dietrich et al., 2011). It was shown that glucocorticoids inhibit the production 
of IL-12, IFN-γ, IFN-α, and TNF-α by antigen-presenting cells (APCs) and T helper 
Th1 cells, but up-regulate the production of IL-4, IL-10, and IL-13 by Th2 cells 
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(Elenkov, 2004). Furthermore, it was found that Dex can inhibit the expression of 
CD40L on PMA/ionomycin-activated peripheral CD4+ T cells (Bischof and Melms, 
1998), and up-regulate the expression of Foxp3 molecule in vitro (Prado et al., 2011). 
Consistent with these and other results, we aimed to use Dex as tolerizing agent to 
induce tolerogenicity in B cells in attempt to mirror the effect of Dex with DCs.  
Our results revealed that Dex decreased the percentage of cells expressing all 
investigated molecules (CD80, CD86, CD40, and MHC II) (Fig. 3.22, 3.23, 3.24, and 
3.25). These results were consistent with previously published data (Berer et al., 2000; 
Griffin et al., 2000; Penna and Adorini, 2000, Piemonti et al., 2000; García-González 
et al., 2013).  
The results of our experiments showed that Dex did not change the distribution of 
main thymocyte subsets (Fig. 3.30).  
The percentage of nTregs generated in vitro did not change in all conditions of co-
culture in the presence of Dex (Fig. 3.31), showing that Dex did not increase the 
potential of the activated splenic B cell to generate thymus-derived Treg cells.  
To check if the presence of Dex in co-cultures induces B-cell apoptosis and in 
consequence lower the number of the generated thymus-derived Treg cells, the 
apoptosis level in B cells after LPS-or IMQ-activation in splenocytes /24h has been 
studied. Our results revealed that the usage of different concentrations of Dex induced 
apoptosis in an acceptable percentage of B cells (less than 25%). Activation by LPS1 
or IMQ1 significantly decreased the percentage of apoptosis induced by Dex (Fig. 
3.32). These results indicated clearly that B cells remain viable in spite of 
administration of Dex, but Dex cannot induce tolerogenicity in B cells most probably 
due to the presence of other factors (LPS or IMQ). Due to the inhibition of Dex pro- 
apoptotic activity the percentage of generated nTregs in the co-cultures of thymocytes 
and B cells remained unchanges as shown in this section. This suggest that 
dexamethasone did not influence the tolerogenic potential of B cells, and the 
generation of nTregs depended on the presence of B cells, the level of their activation, 
and the thymocytes : B cells ratio. 
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4. Conclusions 
Our hypothesis on the role of B cells in the generation of thymus-derived Treg 
cells was built on the following facts: firstly, the normal development of nTreg in the 
thymus requires interaction with thymic antigen-presenting cells such as dendritic cells 
and thymic epithelial cells. These cells are crucial for the selection and maturation of 
thymus-derived Treg cells. Secondly, it was found that a minor percentage of B cells 
reside in the thymus, and the origin and the role of these cells are still poorly studied. 
Thus, to investigate if B cells have the potential to induce the generation of thymus-
derived Treg cells in vitro, we introduced a model of co-culture of thymocytes with 
splenic B cells. Splenic B cells have been used based on the observation of the 
migration of peripheral B cells into the thymus, and thymocytes have been used as the 
source of precursors of nTregs. Based on the results of the study presented in this 
dissertation we can conclude: 
1. Splenic B cells can induce the generation of thymus-derived Treg cells in vitro and 
the percentage of newly generated nTregs is increased upon activation by LPS or 
IMQ. 
2. The percentage of thymus-derived Treg cells generated in vitro was dependent on 
the thymocytes : B cells ratio. 
3. nTreg cells generated in vitro in co-culture with B cells exhibited  the suppressive 
activity. 
4. MHC II and CD80/CD86 molecules expressed on splenic B cells play a major role 
in thymus-derived Tregs generation compared to CD40 molecule. 
5. Thymic B cells activated by LPS or IMQ sustained the viability of  thymus-derived 
Treg cells in vitro by inducing the proliferation of thymic B cells upon activation 
thereby increasing their percentage in the culture and thymocytes : B cells ratio. 
6. Dexamethasone did not affect the generation of thymus-derived Treg cells in the co-
culture with splenic B cells.   
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